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September - 2019

This thesis was submitted in partial fulfillment of the requirements for the de-
gree of Doctor of Philosophy in Computer Science by the Universitat Politècnica
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Abstract
In the last two decades, the data generated by the Next Generation Sequen-
cing Technologies have revolutionized our understanding about the human biol-
ogy. Furthermore, they have allowed us to develop and improve our knowledge
about how changes (variants) in the DNA can be related to the risk of developing
certain diseases.
Currently, a large amount of genomic data is publicly available and fre-
quently used by the research community, in order to extract meaningful and
reliable associations among risk genes and the mechanisms of disease. However,
the management of this exponential growth of data has become a challenge and
the researchers are forced to delve into a lake of complex data spread in over
thousand heterogeneous repositories, represented in multiple formats and with
different levels of quality. Nevertheless, when these data are used to solve a
concrete problem only a small part of them is really significant. This is what
we call “smart” data.
The main goal of this thesis is to provide a systematic approach to efficiently
manage smart genomic data, by using conceptual modeling techniques and the
principles of data quality assessment. The aim of this approach is to populate
an Information System with data that are accessible, informative and actionable
enough to extract valuable knowledge.

Resumen
A lo largo de las últimas dos décadas, los datos generados por las tecnoloǵıas
de secuenciación de nueva generación han revolucionado nuestro entendimiento
de la bioloǵıa humana. Es más, nos han permitido desarrollar y mejorar nuestro
conocimiento sobre cómo los cambios (variaciones) en el ADN pueden estar
relacionados con el riesgo de sufrir determinadas enfermedades.
Actualmente, hay una gran cantidad de datos genómicos disponibles de
forma pública, que son consultados con frecuencia por la comunidad cient́ıfica
para extraer conclusiones significativas sobre las asociaciones entre los genes de
riesgo y los mecanismos que producen las enfermedades. Sin embargo, el manejo
de esta cantidad de datos que crece de forma exponencial se ha convertido en un
reto. Los investigadores se ven obligados a sumergirse en un lago de datos muy
complejos que están dispersos en más de mil repositorios heterogéneos, repre-
sentados en múltiples formatos y con diferentes niveles de calidad. Además,
cuando se trata de resolver una tarea en concreto sólo una pequeña parte de la
gran cantidad de datos disponibles es realmente significativa. Estos son los que
nosotros denominamos datos “inteligentes”.
El principal objetivo de esta tesis es proponer un enfoque sistemático para
el manejo eficiente de datos genómicos inteligentes mediante el uso de técnicas
de modelado conceptual y evaluación de calidad de los datos. Este enfoque está
dirigido a poblar un sistema de información con datos que sean lo suficiente-




Al llarg de les últimes dues dècades, les dades generades per les tecnologies
de secuenciació de nova generació han revolucionat el nostre coneixement sobre
la biologia humana. És mes, ens han permès desenvolupar i millorar el nostre
coneixement sobre com els canvis (variacions) en l’ADN poden estar relacionats
amb el risc de patir determinades malalties.
Actualment, hi ha una gran quantitat de dades genòmiques disponibles de
forma pública i que són consultats amb freqüència per la comunitat cient́ıfica
per a extraure conclusions significatives sobre les associacions entre gens de
risc i els mecanismes que produeixen les malalties. No obstant això, el maneig
d’aquesta quantitat de dades que creix de forma exponencial s’ha convertit en un
repte i els investigadors es veuen obligats a submergir-se en un llac de dades molt
complexes que estan dispersos en mes de mil repositoris heterogenis, representats
en múltiples formats i amb diferents nivells de qualitat. A més, quan es tracta
de resoldre una tasca en concret només una petita part de la gran quantitat
de dades disponibles és realment significativa. Aquests són els que nosaltres
anomenem dades “intel·ligents”.
El principal objectiu d’aquesta tesi és proposar un enfocament sistemàtic per
al maneig eficient de dades genòmiques intel·ligents mitjançant l’ús de tècniques
de modelatge conceptual i avaluació de la qualitat de les dades. Aquest en-
focament està dirigit a poblar un sistema d’informació amb dades que siguen
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Precision Medicine (PM) is an emerging approach for the treatment and pre-
vention of human diseases that takes into account the genetic variability, the
environment and the lifestyle for each person [1]. This approach allows doc-
tors and researchers to predict more accurately which treatment and prevention
strategies will work for a particular disease and in which groups of people.
Today, when a patient is diagnosed with a disease, he receives the same
treatment as others even though it is known that different people may respond
differently to the same treatment. Recent advances in science and technology
have helped to understand why these differences occur, specially in cancer re-
search. For example, it is known that the tumors have genetic characteristics
involved in their growth and spread. These characteristics are different on each
tumor and there are drugs that have been proven effective against cancers with
specific features and uselessness in others [2]. PM helps to identify which treat-
ments are most likely to respond according to the type of tumor, and prevents
the patient from receiving those that are not likely to help. Some of the cancers
which genetic characteristics have been studied are melanoma, some leukemias,
breast, lung, colon and rectal cancer.
One of the pillars of PM that helps to understand the genetic aspects that
make our predisposition to disease and our response to the treatment different
from each other is the genetic diagnosis, which consists in the identification
of potentially damaging variants in the DNA of a patient. The possibility of
doing genetic diagnosis became a reality after the completion of the Human
Genome Project (HGP) in April 2003 [3], that was one of the great milestones
of research in history. Before the HGP, if researchers wanted to identify genes
involved in a specific disease they had to select one or two candidate genes or
specific locations in the DNA sequence to see how often the changes occurred
in the members of the same family [4]. The processess to carry out this type of
research were laborious and didn’t reveal much detail. But the HGP allowed,
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for the first time, to read nature’s complete genetic map of a human being giv-
ing sense of the bigger picture. Since the completion of the project, thousands
of human genomes have been completely sequenced and most of the research
efforts have focused on improving the diagnosis and treatment of diseases, as
well as providing new insights in many fields of biology, including human evo-
lution. Furthermore, the agreements made during the project to encourage the
free distribution of research data allowed scientists to share their findings with
each other, as well as the public. As an example, after an international sym-
posium on 2014, the best genome scientists from more than 20 countries have
come together to improve the cooperation and coordination of genomic medicine
research around the world [5].
1.1 Motivation
Despite all the efforts of the scientific community and even when new knowledge
is accumulated day after day, the human genome is far from being fully under-
stood because the management of the exponential growth of data has become a
challenge for researchers. In this context, a first question to be answered is, what
is the human genome and which role plays in the development of disease?
The human genome is a code represented with 4 letters, called nucleotides -
A (Adenine), G (Guanine), T (Thymine) and C (Cytosine) - that contains the
set of instructions required to build a human being. The complete sequence,
about 3 billion nucleotides, is encoded as large linear DNA molecules within 23
chromosome pairs stored in the nucleus of each cell [6] (see Figure 1.1).
Figure 1.1: DNA, chromosome and cell [7]
The physical characteristics that make us different from each other, the influ-
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ence of the environment over our health and even certain personality traits are
determined by the configuration of this code. Making an analogy with Software
Engineering/Information Systems, any living being is a carbon-based program
(instead of a binary silicon based program) that can be executed following a
model based on four letters (A, C, G and T) [8]. Nevertheless, as a software
program, the human genome may contain defects that can lead to malfunction.
For example, a single letter change (called Single Nucleotide Polymorphism or
SNP) can be responsible for causing a genetic disease. So, how can scientists
identify these small changes in such amount of information?
In order to determine which part of this code is defective, geneticists follow
a process consisting in four main stages: Sample extraction, Primary analysis,
Secondary analysis and Tertiary Analysis.
Figure 1.2: Genomic data analysis workflow
As can be seen in Figure 1.2, in the first place a sample is taken from a pa-
tient (blood, tissue, saliva, etc.). Then, the biological information is translated
into digital data. This is a physical process, called primary analysis, that is per-
formed by DNA sequencing machines such as Illumina and Sanger. Next, the
original data is compared with a reference genome (also known as a reference
assembly) that has been obtained from the DNA sequencing of a set of donors.
The aim of this comparison is to determine the differences (variants) present in
the DNA sample. This is called secondary analysis or variant calling. Complex
algorithms and bioinformatic pipelines are used during this process. Once the
variants are identified, a research must be performed in order to find out if they
are liable of causing a genetic disease. Variants occur normally throughout a
person’s DNA, once in every 300 nucleotides on average, which means that there
are roughly 10 million variants in a single human genome [9]. Most of them have
no effect on health but others can act as biological markers, helping scientists
locate genes that are associated with disease. The identification of relevant
markers is a manual process called variant curation or tertiary analysis, that is
mainly performed by searching and reading scientific literature containing rel-
evant population studies. To accomplish this task and extract accurate results
it is required to gather and manage as much information as possible.
Technological advances such as Next Generation Sequencing (NGS) and the
development of Genome Wide Association Studies (GWAS) have allowed the
collection of huge amounts of data in a cheaper and faster way [10]. But the
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volume of available information increases in a faster pace than the ability of
researchers to connect and analyze it. Additionally, the complexity of human
biology makes this a slow task that requires an appropriate technological sup-
port for its achievement. It is at this point that Genomic Information Systems
(GeIS) gain significance. These systems must support the efficient management
of genomic data that ought to be accessible, informative and actionable enough
to infer valuable knowledge. This is what we call smart data. To this aim,
the GeIS must allow the connection of different knowledge fields such as Ge-
nomics, Proteomics, Pharmacogenomics, etc. under a structured perspective,
and provide appropriate tools to analyze the data and generate new knowledge.
Nevertheless, there are a number of problems, inherent to the domain, that
make the design and implementation of a GeIS a challenge for experts.
1.2 Problem Statement
One of the problems that affect the biological domain is the lack of a clear
ontological basis to define the key concepts of the field. This means that the
same concept can be represented in different and sometimes ambiguous ways.
For example, for decades in clinical practice and laboratory reporting there were
incorrect assumptions about the meaning of mutation and polymorphism.
A thread published 5 years ago in the ResearchGate portal [11], produced a
discusion among more than 300 participants about the difference between a mu-
tation and a polymorphism that is still open. The term mutation is frequently
and erroneously associated with a pathogenic impact, as well as the term poly-
morphism is erroneously associated with a benign impact [12]. Nevertheless,
by definition a mutation is a permanent change in the nucleotide sequence of
DNA that occurs in less than 1% of the population [13]. This definition does
not imply an impact on gene structure or function. In the same way, a poly-
morphism is defined as a DNA variant with a frequency above 1%, that may be
disease-causing. The distinction between mutation and polymorphism on the
basis of their disease-causing capacity can lead to problems of classification. For
instance, there is a type of anemia called sickle-cell anemia that is caused by a
polymorphism which frequency in the population is >1% [14]. In this case, the
disease manifests in people who have two copies of the mutated gene but the
appearance of these two copies in the same individual is rare (<1%). However,
having only one copy of the mutated gene is frequent (>1%) in other popula-
tions where malaria is endemic. These populations have a survival advantage
against the malaria and the mutation is inherited through generations. As a
consequence, a rare variant that causes disease in one population can persist in
another one confering a survival advantage.
Another problem derived from the lack of an ontological commitment is re-
lated to the personalized treatments applied in precision medicine. For instance,
one of the main reasons to sequence the genome in patients with cancer is the
identification of DNA variants in the cancer cells that could be treated with a
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personalized treatment focused on destroying these cells and causing less dam-
age to normal cells [13]. But this requires to classify all the DNA variants of the
cancer cells in order to differentiate them from the variants that are present in
the rest of the cells of the organism. The consequence of a wrong classification
would be a toxic effect derived from applying a wrong treatment that would
affect both cancer and noncancerous cells. This is what currently happens with
chemotherapy, that kill both healthy and cancer cells (see Figure 1.3).
Figure 1.3: Chemotherapy vs personalized treatment.
Besides the ontological problem, there is a second one related to the dis-
persion of genomic information. All the knowledge is spread in over thousand
heterogeneous databases with different sizes, formats and structures. Some of
them are dedicated to one organism: Flybase for Drosophila [15], RMD for
rice [16], GDB for Human [17], etc. Others provide information about specific
parts of the genome: Uniprot for proteins [18], HGMD for genes [19], Reactome
for pathways [20], etc. Each of these data repositories represents a different
and complementary view of the whole genome. But the understanding of the
role that plays each genomic element (genes, proteins, pathways, etc.) requires
more information than is provided by one source. For example, the classifica-
tion of proteins requires the integration of knowledge derived from aminoacid
sequences, gene expression data and known protein-protein interactions [21].
Bringing together all these heterogenous and distributed databases can lead to
interoperability issues related with semantic heterogeneity, data integrity, data
representation and correctness of the interpretation of the data sets obtained
from them. Consequently, the harmonization of the different sources requires to
convert data into a common format and a common structure, which constitutes
a bottleneck in the genomic data analysis workflow.
The third problem to face is that the information may also contain errors
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caused by the complexity of biological processes, the noisy nature of experimen-
tal data and the diversity of sequencing technologies. This results in a great
variability in the quality of the available information. For example, probe de-
sign and experimental conditions are known to influence signal intensities and
sensitivities for many sequencing technologies [21], experiments performed over
a population sample that it is not representative enough can lead to erroneous
conclusions, etc. But the quality problems are not only caused by the infor-
mation itself. If the genomic repositories do not have mechanisms to assure
that the submitted information is correct or represented in the correct format
it can lead to problems such as redundancy, that decreases the reliability both
in the source and the provider. As a conclusion, a huge amount of data is ready
to be used but only part of them are relevant enough to extract meaningful
conclusions.
All the above mentioned problems constitute what we call the “genomic data
chaos” associated to the fact of having a huge number of different, complex and
diverse data sources where the relevant genomic data is stored in partial views
(genes, transcripts, variations, proteins, pathways,etc.), where the holistic per-
spective is missed out, and where there are problems well-known by the data
management community: lack of consistency, different formats for representing
similar data, lack of conceptual standards, as well as difficulties with data het-
erogeneity and data interoperability management. All this leads to data analysis
processes that are mainly manual, tedious and repetitive, with no explicit and
systematic methods, prone to human errors, and making repetitive navigation
through complex hyperlinks unavoidable. This explains why the identification
and management of smart genomic data becomes such a complex task.
On this basis, the design of a proper GeIS requires in the first place a sound
ontological structure to represent and connect the heterogeneous elements of the
domain. Once the structure of the information is clear, the system must support
its efficient management. Thus, it is essential to define a systematic process,
from the selection of the appropriate data sources and the identification of rele-
vant data, to the final load and exploitation to extract valuable knowledge. But
the reliability of the results is highly dependent on the quality of the information
managed. This is why the GeIS must count on mechanisms to ensure that the
results obtained during the process are of enough quality.
In a previous thesis work [22], the Conceptual Schema of the Human Genome
(CSHG) was developed with the aim of providing a clear and precise understand-
ing of the human genome. This goal was achieved by unambiguously describing
the relationships between the biological concepts under a holistic perspective.
As a continuation of this work and using the CSHG as ontological background,
this thesis proposes the definition of a method for the efficient management of
smart genomic data, as basis for the development of sound Genomic Information
Systems.
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1.3 Objectives and Research Questions
In this section we formulate the research questions that are answered in this
dissertation in order to achieve four main goals: determine the problems that
hinder the management of genomic information (OB1), provide a method for
the efficient management of genomic information (OB2), provide a set of quality
criteria to ensure that data are reliable and correct (OB3), and validate the
contribution of this research work (OB4).
Following the structure provided by Wieringa [23], the research questions
are divided into two categories: Knowledge Questions (KQ) are asked to gather
information about the world, and Design Problems (DP) call for the design
of an artifact that will improve a problem context and contributes to answer
knowledge questions.
Our research starts by obtaining information about the domain of interest
in order to determine the problems that hinder the management of genomic
information (OB1). This results in a set of knowledge questions:
• Where can the genomic information be found (RQ1)?
• Which problems arise when managing genomic information (RQ2)?
Once the characteristics of the problem domain have been established, our
aim is to provide a method that is expected to improve the management of
genomic information (OB2). This leads to a set of design problems:
• How can the most suitable genomic data sources be found (RQ3)?
• How can the relevant information be identified (RQ4)?
• How can the information be structured and stored for its further exploita-
tion (RQ5)?
Once the solution to efficiently manage the information has been established,
we need to ensure that the data are reliable and correct (OB3). At this point a
new knowledge question and a new design problem arise:
• Which are the criteria that genomic information must fulfill to ensure its
quality (RQ6)?
• How can the quality of genomic information be measured (RQ7)?
Finally, we need to confirm our contributions and validate the proposed
solution (OB4) by answering the following research questions:
• To which extent are the results of our method accurate and valid (RQ8)?
• Do domain experts think that our method is useful to manage genomic
information (RQ9)?
In the next section, we present the research methodology followed to achieve
the goals and answer the research questions.
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1.4 Research Methodology
This research has been developed by using the design science approach of Wierin-
ga, defined as the design and investigation of artifacts in context [23].
In this thesis, we define a method (the artifact) to manage genomic infor-
mation in an efficient way (the context) with the aim of populating Genomic
Information Systems with high quality data.
Figure 1.4: Design circle of the research methodology followed in this thesis.
The research has been outlined as an engineering cycle and at the basis of
this approach is the design cycle, consisting in three phases:
• Problem Investigation: in this phase we describe the problem context,
who the stakeholders are and how their goals can be achieved.
• Treatment Design: in this second phase, we provide a treatment as the
introduction of an artifact in the problem contex.
• Treatment Validation: in the third phase, we validate the treatment
in order to provide evidence that the artifact helps the stakeholders to
achieve their goals.
Following the design science approach, the technological transfer associated
to the real-world design and implementation is out of the scope of this PhD
project. Figure 1.4 shows the key points of this thesis according to each phase
of the engineering circle.
According to this approach and the objectives described in section 1.3, we
start this research work performing an analysis of the state of the art in order
to understand the domain and have a deep knowledge of the problem context.
This analysis will help us to determine the characteristics of the genomic data
sources, identify existing approaches to structure genomic information under
a conceptual modeling perspective, and determine the quality of the available
information. Next, we verify that there is not a current solution for the problem,
and we state the treatment design. It consists in the definition of a method to
efficiently manage genomic data, and the criteria required to ensure the quality
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of the information. Finally, we validate that the proposed method is useful
to solve the problem and achieve the goals of this thesis, using epilepsy and
migraine as main case studies, as well as Crohn disease and male breast cancer
as complementary case studies.
1.5 Thesis Outline
This thesis is structured in 5 chapters and 5 appendices, according to the three
main phases described by the research methodology (Problem Investigation,
Treatment Design and Treatment Validation):
• Chapter 2 introduces the problem investigation. In this chapter we ana-
lyze the characteristics of genomic data sources, their role as key elements
to gather the scientific knowledge and their evolution in the last years.
Next, we present a brief history of existing works focused on modeling
genomic information and the usefulness of the Conceptual Schema of the
Human Genome as basis to develop information systems that are capa-
ble of connecting this knowledge under a solid conceptual structure. Fi-
nally, we present an analysis of the genomic information available for the
scientific community in order to characterize the quality problems that
hinder the efficient management of the information. These problems are
structured according to six major dimensions: accessibility, completeness,
consistency, currency, redundancy and reliability.
• Chapter 3 presents the treatment design. In this chapter we describe the
solution proposed to solve the problems described in Chapter 2, consisting
in a method to efficiently manage genomic data, from the selection of the
adequate data sources to the exploitation of the information to extract
valuable knowledge. In addition, the criteria required to ensure the quality
of the information managed during the process are defined.
• Chapter 4 focuses on the validation of the treatment in four real cases:
epilepsy, migraine, Crohn disease and male breast cancer. The results of
the process are reviewed by a group of experts in genetic diagnosis which
will allow us to prove the validity of the proposal and the achievement of
the objectives.
This thesis ends up with the conclusions and summarizes the main contri-
butions of this work to the scientific and academic community, as well as a




The sequencing of the first human genome, took $2.7 billion and almost 15
years to be completed [24]. Since then, the advances in sequencing technologies
and the development of new laboratory techniques have allowed the scientific
community to sequence DNA in a cheaper and faster way. For example, the
cost to generate a whole-exome sequence nowadays is generally below $1,000
and takes a few hours [25]. As a consequence, these practices have become a
routine research tool, allowing the development of multitude of research projects
around the world. According to [26] about 15,000 sequencing projects have been
completed and over 75,000 more are on the way.
In order to gather all the generated knowledge and make it publicly avail-
able for the scientific community, a huge amount of genomic repositories have
been developed. Nevertheless, what at first was a great advance to carry out
new research projects turned into a handicap and has generated a first difficult
question to be answered by researchers, where should I go to find the genomic
data I need?
2.1 Genomic Data Sources
The majority of the online resources are specialized databases that provide
not only information about DNA sequences, but also data on gene expression,
macromolecular structures, gene-disease associations and genotype frequencies
in diverse populations. This means that the information required to succeed in
a complex research is not usually available in only one data source. Frequently,
several heterogeneous databases must be queried in order to join all the puzzle
pieces together, what makes the finding of the adequate repositories and the
connection of the stored information a task that is not trivial at all.
Nowadays, there is no way of knowing with certainty the number of active
genomic data sources, which introduces an element of uncertainty in a field
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that requires the management of the most accurate and updated data. The
problem is due to the fact that the information about these online resources
is scattered in several life science journals and around the Web [27]. Actually,
only a few web sites provide a guided access in the form of searchable links to
most of them. In order to have a clue about the magnitude of the problem we
head to catalogs such as the NAR Molecular Biology Database Collection1, the
Online Bioinformatics Resources Collection2 or the one provided by the Human
Genome Variation Society3.
The Nucleic Acids Research (NAR) is an open-access and peer-reviewed
scientific journal published by Oxford University Press. The journal publishes
each year a special issue dedicated to categorize many of the publicly available
online databases related to biology and bioinformatics. According to the issue
published on January 2019 [28], the resulting database called the Online Molecu-
lar Biology Database Collection contains information about 1,656 repositories,
divided into 15 main categories and 42 subcategories (see Figure 2.1).
Figure 2.1: Number of databases added and removed from the Online Molecular
Biology Database Collection from 2014 to 2019.
The Online Bioinformatics Resources Collection (OBRC) at the Health Sci-
ences Library System (HSLS), currently includes 2,458 online bioinformatics
databases divided into 13 main categories and 53 subcategories. The categories
are created dynamically based on the textual information retrieved.
The Human Genome Variation Society (HGVS) promotes the collection,
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Nowadays, the society maintains a collection of links to 1,750 databases.
Besides the increasing number of databases to be queried, a significant num-
ber of them can become obsolete quickly, as can be seen in Figure 2.1. The
reason why this happens is due to most of these repositories are developed ad
hoc for specific projects and over time they lose the technological maintenance
or the information stored is no longer updated.
In spite of the collective efforts made by the scientific community to help
researchers to face the growth of genomic repositories, the mentioned catalogs
are mere lists of links that differ in the categorization of the content, the quality
of the annotations and in their coverage. Therefore, they can be a starting point
but not a feasible solution to find and connect the most appropriate sources for
each circumstance.
In the next section we describe how conceptual models can provide the
ontological support required to achieve this goal.
2.2 Conceptual Modeling for Genomics
The understanding of complex systems requires the integration of genomic
data under well-constructed conceptual structures to describe the relationships
between their components under a holistic perspective. However, genomic
databases differ not only in the scope of the information they represent, but
also in the way the same information is modeled. This situation hinders the
process of retrieval, annotation and integration of heterogeneous datasets as
well as the quality of the conclusions derived from their analysis.
When the research community realized that this issue was becoming an im-
portant problem, some solutions were proposed. The first approach was to
construct ontologies, with the aim of unifying knowledge and making it in-
teroperable through consistent vocabularies. Examples of such a well-known
type of ontologies are Gene Ontology (GO) [29], which describes biological pro-
cesses, cellular components and molecular functions; Sequence Ontology (SO)
[30], which describes the features and attributes of biological sequences; and
Variation Ontology (VariO) [31], which defines the effects, mechanisms and se-
quences of genomic variants. But these ontologies are essentially large termino-
logical resources that describe the terms used in the domain. Consequently, they
cannot be considered as “ontologies” in the foundational and more philosophical-
oriented sense associated to the term in the Information Systems domain. Nei-
ther as a concrete engineering artifact designed for a specific purpose and rep-
resented in a specific language as it is the case in the Artificial Intelligence or
Semantic Web contexts [32]. As a result, for example it is not obvious how to
connect these ontologies and derive a global database schema from them to the
benefit of developing information systems for genomic data. For such task, the
use of conceptual models proves to be a powerful tool, intended to provide an
accurate representation of the relevant concepts of the domain (in ontological
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terms, a representation that approximates as well as possible to what should be
considered an ideal foundational ontology of the domain).
Conceptual modeling is defined as the “activity that elicits and describes the
general knowledge an Information System needs to know” [33]. This description
is called a conceptual schema and it is widely accepted that its use helps the
understanding of complex domains by making a clear definition of the entities
involved and the relationships among them.
The idea of applying conceptual modelling to understand the genome has
been explored by some authors. It was firstly introduced in 1995 by Chen et
al [34] to describe how an extended object data model can be used to capture
the properties of scientific experiments. Then, Okayama et al [35] described the
conceptual schema of a DNA database and Médigue et al [36] included models for
representing genomic sequence data. In 2000, Paton et al [37] presented a set of
data models to describe elements involved in transcriptional and translational
processes, as well as the variant effects generated by them. Later on, Ram
et al [38] applied conceptual modeling principles in the context of 3D protein
structure and more recently, Bernasconi et al [39] proposed a conceptual model
for describing metadata of experiments. In any case, these approaches still
focus on specific parts of the domain, they are unconnected from each other
and do not provide the required global view to understand complex biological
systems.
The Conceptual Schema of the Human Genome (CSHG), designed by the
PROS Research Center at the Universitat Politècnica de València (UPV), has
been developed to fill the gap and provide a unified conceptual perspective
to the partial views that each database addresses in particular [40]. The 3rd
version of the model maintains the essential genome information through 5 main
conceptually integrated views:
• The Structural View, describes the structure of the genome.
• The Transcription View, describes the components and concepts related
with the protein synthesis process.
• The Variation View, describes the changes regarding the sequence of ref-
erence.
• The Pathway View, describes information about metabolic pathways.
• The Bibliography and Data Bank View, describes where the data comes
from.
It is due to its completeness that the CSHG has been selected to establish the
ontological background required to bring some structure to the chaos introduced
by the growth, size and heterogeneity of genomic databases. But the genomic
data chaos problem goes further and once the structure of the information is
defined another question arises: is all the available information useful to generate
relevant knowledge?
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2.3 Data Quality for Genomics
Due to the experimental nature of the genomic domain, the information is sus-
ceptible of containing errors or be inaccurate [41]. These errors can be propa-
gated through the data sources, increasing the noise and forcing the researchers
to make a great effort to separate the wheat from the chaff. Even though data
quality has been studied for decades, research on the quality of genomic data has
just started and there are not sound results yet. For example, some research
has been done in order to determine the quality of a biological data source,
such as the one made by the Human Variome Project [42]. This proposal en-
comprises a set of quality criteria divided into 4 main categories: data quality,
technical quality, timeliness and accessibility. Nevertheless, it is focused only
on databases that store information about DNA variants and it still has no im-
plementation due to the difficulty of gathering all the required metadata, which
needs a dedicated team for the manual collection and evaluation of part of the
items.
In order to understand the issues that affect the quality of genomic infor-
mation in general, we performed a study of the most common errors present in
different well-known genomic data sources [43].
Table 2.1: Data Quality Dimensions
Dimension Definition
Accessibility The extent to which data is available or, easily
and quickly retrievable.
Completeness The extent to which data is not missing and
all necessary values are represented.
Consistency The extent to which data is consistent between
systems and represented in the same format.
Currency The extent to which data is sufficiently up-to-
date for the task at hand.
Redundancy The extent to which the database has redun-
dant data or duplicated records.
Reliability The extent to which data is regarded as true
and credible.
This study allowed us to classify the issues found into six major categories
called dimensions: Accessibility, Completeness, Consistency, Currency, Redun-
dancy and Reliability. In Table 2.1 the description of each dimension is shown.
Accessibility issues. Even though most of the information stored in the
genomic repositories are publicly available, there are some issues that can hin-
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der the access, such as restrictions or the lack of mechanisms to automatically
query and download the results of a search. Even when these mechanisms are
provided, sometimes they only grant access to a view of the data which can lead
to completeness issues. For example, the Ensembl database provides an tool
to mine the stored information called BioMart 4. This tool allows the user to
query some predefined data sets as well as select the fields to retrieve from the
database. But for example, one of the missing fields is the type of DNA variant
that is very important to classify them according to the type of change that
occurs in the DNA sequence.
Completeness issues. Besides the errors that can occur during the DNA
sequencing, the process of marking specific features in a DNA sequence with
descriptive information about its structure or its function, called sequence an-
notation, it is error prone too. These annotations serve as a starting point for
assessing the state of the art in a particular field, or as a source for the inter-
pretation of experimental results. But due to the extensive and ever growing
amount of available information, manual annotation is a time-consuming task
so tools for automated processing and analysis of text are being developed to
assist researchers in evaluating the scientific literature [44]. Although these tools
speed up the annotation process, the heterogeneous nature of written resources
and the difficulties of extracting knowledge embedded in free text (inconsis-
tent gene nomenclature, domain-specific languages and restricted access to full
text articles) make the automated extraction of relevant biological knowledge
a not trivial task. For example, the identification of relationships between pro-
teins or the interaction between drugs and proteins is the basis to understand
the metabolic pathways. To do this in practice, the automated curation tools
would have to be able to mimic the human ability to infer connections from text.
Despite the huge advances in these technologies, the information annotated with
these tools can be incomplete, leading to problems such as the presence of miss-
ing values which affect the completeness of the databases.
Consistency issues. In order to obtain meaningful results, it is important
to incorporate information from different biological repositories into the analysis.
If data structures were consistent among systems, the integration from differ-
ent resources would be easy. But genomic databases are very diverse, making
extremely laborious to perform even simple queries across databases. As there
is no standard format for genome data storage and no commonly accepted vo-
cabulary, consistency problems are specially significant when dealing with the
terminology used to represent biological concepts. An example of these consis-
tency problems is the classification of the type of DNA variants, which number
ranges from 8 types (according to the HGVS recommendations) to 31 (accord-
ing to the ClinVar database). Even when an ontology is used as basis, some
databases map these concepts to their own ‘display’ terms where common usage
differs from the ontology definition, as happens in the Ensembl database.
Currency issues. Another cause of low quality is related to the currency
4www.ensembl.org/biomart/martview/
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of the information. As the underlying concepts are imperfectly defined, and
scientific understanding of them is changing over time, the annotation of most
genomes becomes outdated. Nevertheless, as has been shown in Figure 2.1,
there are databases that do not have the required technological maintenance
or do not review the information stored so they become obsolete quickly. As
a consequence, most genome annotations remain static for years or have never
been changed since their initial publication [45]. Another problem derived from
the lack of updating processess is the presence of old identifiers that can lead
to redundancy issues or errors in the analysis of the stored information. For
example, the dbSNP database stores information about DNA variants and when
there are multiple DNA changes referring to the same location, they are grouped
into one cluster and are assigned a reference ID number, called rs number or rs
identifier. If later on two cluster records are found to map to the same location
(i.e. are identical), then dbSNP merges those records and consequently, the IDs
become obsolete. Thus, it is crucial to take this situation into account when
repeating a research after a period of time or when integrating information from
different sources. If one of them has old rs numbers, the results of the integration
process can be wrong.
Redundancy issues. As the information grows, the above mentioned pro-
blems converge into the increase of redundancy in the information collected.
The same data can be submitted by different research groups to a database
multiple times, or to different databases without cross-reference. An updated
version of a record can be entered while the old version still remains. Or there
may be records representing the same entity, but with different sequences or
different annotations [46]. As high level of redundancy leads to an increase in
the amount of data to be processed internally by the database and externally
by the users. It also hinders the annotation process creating confusion and re-
quiring additional time and effort to resolve missing, duplicate or inconsistent
fields. The developers of some well-known databases realized that redundancy
was becoming a noteworthy problem and started to use de-duplication processes
in their datasets. For example, since UniProt release 2015 04, a Proteome Re-
dundancy Detector was used in order to discard entries belonging to redundant
proteomes of bacterial species in the not reviewed UniProtKB (TrEMBL) set.
After applying the method for the first time, 46.9 million entries were removed
from the database (see Figure 2.2).
Reliability issues. The problems mentioned above lead to a decrease in the
reliability of the stored information. To minimize these issues, some databases
are supported by external experts that manually review the information and
correct the errors found. Nevertheless, this is a laborious process that together
with the lack of well-constructed information systems are the reason why the use
of these repositories is not an extended practice yet, hindering the exploitation
of the full potential that these databases can offer.
18 CHAPTER 2. PROBLEM INVESTIGATION
Figure 2.2: Impact of the Proteome Redundancy Detector in the growth of the
Uniprot database.
2.4 Conclusions
Throughout this chapter, we have referred to the impact that advances in se-
quencing technologies and laboratory practices have in the growth of genomic
data. Thus, the first research question we aimed to answer was where to go
in order to find the information required to understand the human genome
(RQ1).
As we have seen, thousands of heterogeneous databases are publicly avail-
able so geneticists and researchers are forced to delve into a lake of information
in order to validate their experiments and extract meaningful conclusions. Fur-
thermore, in order to understand complex systems several databases must be
queried. But the finding of the adequate repositories and the connection of the
stored information is not a trivial task. Most of the genomic repositories gather
information about specific parts of the domain and lack of a conceptual struc-
ture to make them interoperable. On the other hand, there is a vast amount of
data ready to be explored but only part of them is valuable to serve as a source
for interpretation of experimental results. With this in mind, the next research
question we aimed to answer was to identify the main problems to face when
managing these type of data (RQ2).
After a study performed over some well-known genomic repositories, we have
seen that due to the complexity of the biological domain, the specificity of the
experiments and the characteristics of the databases, the genomic information
is susceptible of containing errors or be inaccurate. There may be records rep-
resenting the same entity (redundancy), but with different DNA sequences or
different annotations (consistency problems). The limitations of the tools used
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to mine the biomedical literature lead to the presence of missing values in the
databases (low completeness) and the lack of maintenance causes the informa-
tion to become obsolete (currency problems). All these issues decrease the relia-
bility of the repositories and increase the effort required to find the information
useful to solve innovative research hypothesis.
The aim of a Genomic Information System (GeIS) must be to solve, or at
least minimize, the impact of the above mentioned problems, decreasing the
risk of inconclusive and potentially invalid results. To this end, a systematic
approach is required in order to reduce the effort that researchers must invest
in so time-consuming tasks such as the selection of the adequate data sources,
the identification of high-quality data, and the management of the information




In the previous chapter, we have looked at the context of this research and the
challenges that must be faced when managing genomic information. With the
aim of providing a feasible solution, throughout this chapter we describe the
main contribution of this thesis: a method to manage genomic information in
an efficient way to populate a GeIS with high-quality data. We move towards
this goal by solving the following design problems:
• How can the most suitable genomic data sources be found (RQ3)?
• How can the relevant information be identified (RQ4)?
• How can the information be structured and stored for its further exploita-
tion (RQ5)?
The solution to these design problems constitute the core of our approach,
the SILE method, that is described in detail throughout section 3.1. Neverthe-
less, as has been mentioned in chapter 2, once the solution to efficiently manage
the information has been established, we need to ensure that the data are reli-
able and correct. As this requires to face a set of quality challenges, we must
tackle a new knowledge question and a new design problem:
• Which are the criteria that genomic information must fulfill to ensure its
quality (RQ6)?
• How can the quality of genomic information be measured (RQ7)?
Throughout section 3.2, we answer the above mentioned questions by ex-
ploring the concept of Data Quality, adapting it to the genomic domain, and
describing what is a Data Quality Methodology in this context. Next, we propose
a quality framework that complements the SILE method to ensure that the data
managed are of enough quality to extract meaningful conclusions. The goal to
be achieved is to provide correct data that could be used in any GeIS-oriented
software platform intended to interpret those data and generate valuable clinical
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information in real PM settings (as for instance the VarSearch/GenesLove.Me
platform [47] developed in the context of the PROS research center, a natural
software platform to check the application of the results of this PhD work).
Finally, section 3.3 contains the summary and conclusions of this research
work.
3.1 The SILE Method
A GeIS must provide support to four main tasks: i) search for reliable data
sources, ii) identification of relevant information, iii) adequate data storage and
iv) exploitation of the information and knowledge generation. The mentioned
tasks must be performed in a systematic way and due to the characteristics
of the domain, it is essential to define a method with a solid ontological back-
ground.
To this end, the main contribution of our research work is the SILE method,
which acronym refers to the stages that make it up (Search, Identification, Load
and Exploitation). A brief description of each stage of the method can be seen
in Table 3.1.
Table 3.1: Description of each stage of the SILE method
Stage Description
Search Search and selection of the adequate data sources to
extract information from.
Identification Identification of the relevant information to satisfy a
knowledge requirement.
Load Storage of the information for its further analysis and
exploitation.
Exploitation Extraction of knowledge from the database by using
specific tools to analyze and interpret genomic data.
The core of this approach is the CSHG, which provides the conceptual struc-
ture required to connect all the data sources and the stored information under a
holistic perspective. In the next sections, we present in detail the main purpose
and activities that take place on each stage of the SILE method.
3.1.1 Search
The aim of the Search stage is to identify the genomic repositories that store
the information required to succeed in fulfilling the goals of a defined task.
As has been seen in Section 2.1, the vast majority of the information gene-
rated by biological research centers and biotechnological world-wide consortia
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are publicly available to be used by the community: over thousand repositories
of open genomic data, that help biologists and clinicians to tackle complex
diseases in a multidisciplinary and individualized way. Each repository gathers
information from different biological contexts that must be connected in order
to infer meaningful conclusions. This has become a challenge for researchers
because the existing catalogs differ in the categorization of the data sources and
do not provide an intuitive way of representing the connections among them. As
a result, the researchers usually search for information in a small set of familiar
databases, with the consequent loss of sources that could be essential for their
work. To solve this problem, the CSHG has been used to classify the genomic
data sources according to their content, as well as a roadmap to identify which
repositories are required.
For example, given a certain task such as the identification of DNA variants
associated to a disease, the CSHG provides the context of the information that
must be searched, and which type of genomic repositories must be queried. In
this case, the researcher must focus on querying data sources specialized in the
disease of interest (phenotype), the changes in the DNA that are associated to it
(the DNA variants and their frequency of appearance in the studied population),
their structural context (position in the genome), the functional consequences


















Figure 3.1: Simplified view of the CSHG required to identify variant-disease
associations.
Moving through the different views of the CSHG, different tasks can be
solved and as long as more details are required, additional parts of the schema
can be easily added, such as proteins or pathways.
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Once the context of the information to be searched is established, the next
step is to identify the specific sources associated to each entity of the CSHG.
To ease this task, the repositories collected by the NAR catalog, the OBRC
collection and the HGVS society have been studied in depth and mapped to
each element of the CSHG [48]. Using a graphical interface developed for this
purpose, the researcher can navigate along the conceptual schema and access
the databases that provide specific information about the elements of interest
in three levels of depth: view, class and attribute (Figure 3.2).
Figure 3.2: Graphical tool for searching genomic databases according to the
CSHG [48].
This approach helps the researcher to explore new data sources, identify
which ones are the most adequate to extract information from, and to ensure
that no relevant repositories have been left aside.
3.1.2 Identification
Once the most adequate repositories to be used as data sources have been se-
lected, the next step is the identification of the relevant information to solve
a defined task. To this end, we need to extract only the required information
from the selected databases and integrate it under a holistic perspective. The
CSHG provides the attributes required to precisely represent each entity, as well
as defines how they must be connected to ease their further integration.
Each repository often provides different ways of accessing the stored data.
Thus, the first step of the Identification stage is to determine the different access
that each data source provides, as well as which one is the most adequate for
the task at hand. For example, the ClinVar database provides three ways of
accessing its content: i) direct download through the web browser, ii) access via
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API and iii) download of the VCF1 files stored in the FTP site. Each access
provides a different level of coverage according to the CSHG, being the VCF
files useful for exploratory analysis but not for a deep understanding of the
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XML files and the API
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VCF files
Figure 3.3: Differences in the information coverage according to the type of
access to the ClinVar database. Filled boxes represent the entities for which
information can be extracted. White boxes represent the entities which infor-
mation is not provided.
As has been mentioned in chapter 2, each database represents the informa-
tion with different format and structure, which hinders the integration process.
Thus, once the way of extracting the information from each repository is de-
termined, it needs to be harmonized into a common data model so it could be
loaded into a database for its further exploitation.
To this aim, it is necessary to establish the conceptual correspondence be-
tween the information stored in the databases and the elements represented in
the CSHG as a set of mapping rules. Furthermore, it is essential to identify
the discrepancies in the definition of the biological concepts and the content of
each field (allowed values, variant name format, ontology used, etc.) in order to
describe a set of transformation specifications to represent the information un-
der a unified perspective that ease its further integration and management. For
example, the Ensembl database considers 8 types of variants while the CSHG
considers 7 types. Each variant type in the source of origin must be mapped to
the corresponding term in the target schema, including those that do not have
1Variant Call Format, a widely accepted file format to manage information about DNA
variants, with the main feature of declaring the file structure in the file itself through an initial
section of metadata
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a direct correspondence: Substitution and Traslocation. Both discrepancies can
be solved by heading to the definitions provided by Ensembl2 and comparing
them with those provided by the CSHG [22]:
• Substitution: The Ensembl database defines a substitution as “a sequence
alteration where the length of the deleted sequence is the same as the length
of the inserted sequence”. This type of variants can be considered as a
special case of Indels, described by the CSHG as ”an insertion and a
deletion that affects two or more nucleotides”.
• Translocation: The Enmsebl database defines a translocation as “A region
of nucleotide sequence that has translocated to a new position”. This type
of variation can be considered as a special case of Insertion, described by
the CSHG as ”an insertion of a nucleotide sequence in a certain position
of the DNA”.
In Table 3.2, the correspondences among the types of variants according to
the CSHG and the Ensembl database are shown.
Table 3.2: Correspondence between the Ensembl database and the CSHG vari-
ant classification.
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Both mapping rules and transformation specifications, require an exten-
sive knowledge of the schemas used by each genomic repository and the tar-
get schema, the CSHG. This is a simple case used to illustrate the example;
nevertheles, the problem incrases depending on the discrepancies between the
databases.
In order to perform the steps described in this stage of the method, the
raw information from the genomic repositories are stored into a temporary data
2www.ensembl.org/info/website/glossary.html
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storage from which they are integrated and transformed following the common
structure provided by the CSHG.
3.1.3 Load
The aim of the Load stage is to convert the transformed data into a queryable
format that allows their further management and exploitation. To this end, a
database that complies with the structure provided by the CSHG is needed, as
well as the mechanisms to store the data in the target database.
The success of the load stage depends on what is going to be done with the
data once it is loaded into the target database. Some uses could be:
• Perform data analysis.
• Create a tool for search and data exploration.
• Build machine learnign algorithms to infer knowledge.
Another key consideration before performing the load process is to under-
stand the requirements of the work that is going to be performed by the target
environment: the volume of data to be managed, their structure, the technology
used, and the type of load required.
Additionally, this process requires the raw data to go through a data valida-
tion process, including control of duplicates and input data checks for constraints
derived from the technology used in the implementation of the target database.
For example, for relational databases there must be checks for orphan foreign
key values (e.g. values which are present in a foreign key column but not in a
primary key column).
3.1.4 Exploitation
The aim of the Exploitation stage is to extract knowledge from the information
stored in the database. As has been seen in Section 1.1, one of the tasks that can
be performed is to provide support to the variant curation process or tertiary
analysis, key for the enhancement of Precision Medicine (PM). One of the pillars
of PM is the genetic diagnosis which consists in the identification of potentially
damaging variants in the DNA of a patient. To this end, a tool called VarSearch
[47] has been developed by our research group.
The information about the variants present in a biological sample are stored
in Variant Call Format (VCF) files, a standard widely accepted by the biological
community [49]. The VCF files are processed by VarSearch in order to determine
which variants within the file are also among those stored in our database.
As a result, a personalized report is generated, indicating the risk of suffering
the disease (see Figure 3.4). Furthermore, VarSearch allows the researcher to
go into detail on the characteristics of the variants found, and the evidence that
corroborates their relationship with the disease of interest. This tool provides
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Figure 3.4: VarSearch Framework.
support to the researchers in the genetic data analysis, reducing the time and
effort required to determine the variants present in a sample.
The possibility of applying SILE to identify and manage correct data for any
phenotype under research conforms an ambitious research challenge, that could
lead to a global Genome Database where all the relevant information for any
phenotype of interest could be accessible for the adequate stakeholders. In PM
terms and moving to the clinical context, this would mean to have a holistic
(conceptually-speaking) repository that would include all the information re-
quired to perform a correct and valuable genomic diagnosis. Considering that
the genome is not only a human feature, but the way in which life manifests in
our planet, the level of this scientific challenge is amazing. The work presented
in this PhD thesis provides a solution to move in this direction, with a concrete
method (SILE) and a sound conceptual modeling basis. Other approaches to
extract knowledge from the stored information are oriented to the development
of tools to enhance data discovery, enlarge visualization, allow the performance
of data analysis operations and contextualize data by augmenting it [50]. To
this aim, a specific research on the use of interaction patterns are open and thus
out of the scope of this thesis.
Along Section 3.1, we have described a method called SILE to solve three
main design problems: How can the most suitable genomic data sources be found
(RQ3), how can the relevant information be identified (RQ4) and how can the
information be structured and stored for its further exploitation (RQ5).
Due to research in Genomics is under constant evolution, new data sources
arise, and because of the experimental nature of the domain, the information is
susceptible of containing errors or be inaccurate. Thus, two new design problems
arise: Which are the criteria that genomic information must fulfill to ensure its
quality (RQ6)? and how can the quality of genomic information be measured
(RQ7)? In the next section we present a quality framework that enriches the
SILE method and ensures that the information managed is reliable and cor-
rect.
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3.2 Data Quality Assessment
Since genomic data are prone to errors and quality issues, it is important to
assess their quality to achieve advantage through their analysis. Furthermore,
decision making based on low genomic data quality may involve serious mis-
takes with important consequences when applied with clinical purposes. But,
before one can address issues involved in analyzing and managing quality in the
genomic domain, it is important to well understand what Data Quality (DQ)
means.
DQ has been defined by Wang and Strong [19] as “fitness for use”, i.e. the
ability of a data collection to meet users’ requirements. DQ is evaluated by
means of different dimensions that can be assessed by using specific metrics in
order to get a quantitative measure that represents the quality of the data being
managed. But to apply this knowledge properly a sound methodology needs to
be defined.
Along Section 3.2.1, we review what a data quality methodology is and how
it can be applied to the context of genomics. Then, in Section 3.2.2 and Section
3.2.3 we apply the methododoly to assess the quality of genomic repositories
and genomic information.
3.2.1 Data Quality Methodology for Genomics
A Data Quality Methodology (DQM) can be defined as a “set of guidelines and
techniques that, starting from the input information concerning a given reality
of interest, defines a rational process for using the information to measure and
improve the quality of data of an organization through given phases and decision
points” [51]. To this aim we have defined a DQM specifically for the genomic
domain in order to i) ensure Veracity through the selection of high-quality repos-
itories and ii) provide Value by extracting the highest quality data from each
one [52]. The proposed DQM is divided into 4 phases: Dimension Description,
Metric Description, Requirements Description and DQ Assessment.
Dimension Description. Starting from a detailed description of the know-
ledge requirements to be solved, the first phase of the methodology consists in
describing the interesting dimensions to be measured and their scope. The selec-
tion of relevant dimensions in a given scenario is mostly application-dependent.
For example, while Currency is a key dimension to determine quality of a ge-
nomic database, when measuring the quality of a specific variant for genomic
diagnosis we should focus on Reliability.
Metric Description. This phase consists in describing the metrics associ-
ated to each dimension. The same dimension can be used to assess quality in
more than one scenario and is distinguished by the metrics defined on each case.
As an example, Reliability can be measured by two different metrics depending
on the context:
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• Believability of a database: a metric to measure this dimension is that the
database must be supported by well-known institutions and its content
reviewed by experts.
• Believability of a variant: a metric to measure this dimension is that there
must be at least one publication with credible statistics to support the
association between the variant and the studied disease.
Requirements Description. In this phase of the DQM, the minimum
levels of quality that must be fulfilled are specifically determined by assigning
concrete acceptance criteria to each metric. For example, the number of publi-
cations about a gene-disease association must be at least one, the participants
in a case-control study must be at least 700, etc.
DQ Assessment. Once the dimensions, metrics and minimum require-
ments are established, a sound data quality assessment can be made by compa-
ring the collected information and the minimum acceptance criteria that have
been defined in the previous phase.
The most important tasks that are affected by the quality of the information
when performing a tertiary analysis are i) the selection of the genomic data
sources and ii) the identification of accurate information. In the next subsection,
we explain how the proposed methodology can be connected to the SILE method
to support the development of these two tasks.
3.2.2 Data Quality Assessment of Genomic Repositories
Genomic data sources with missing, incomplete or erroneous information hinder
the processing and analysis of data. Consequently, experiments based on these
sources can yield to incorrect results. Such problems lead to a loss in confidence
in the underlying data sources or the provider of the data, and to a rise in
effort and frustration for the researcher [41]. Thus, underlying high-quality
repositories is of utmost importance.
Taking into account the characteristics of the genomic data sources and the
problems described in Section 2.3, the previously defined DQM is useful to
determine those repositories with the higher quality according to our require-
ments.
The first step of the methodology includes the selection and definition of
the quality dimensions that are going to be measured. We consider a genomic
repository of high-quality if it can be regarded as true and credible, sufficiently
up-to-date and also has mechanisms to easily access the information. Thus, the
quality dimensions that we are going to measure are: Reliability, Currency and
Accessibility.
The next step is to describe the metrics to measure each dimension and
the criteria that must be fulfilled. Table 3.3 shows the metrics and the quality
criteria for each dimension.
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Table 3.3: Metrics and criteria of acceptance for the assessment of genomic
repositories
Dimension Metric Criteria of acceptance
Reliability
M1: Curation Process The information must be manually curated or
reviewed by an expert team.
M2: Submission Process. There are quality controls to ensure the cor-
rectness of the submitted data such as sub-
mission forms, automated control for HGVS
expressions, etc.
Currency M3: Database Update
The date of last update is less than 1 year.
The link to the database is active.
Accessibility
M4: Database Availability The information stored must be public and
freely accessible.
M5: Information Access The database provides mechanisms to extract
the information such as API, FTP repository,
etc.
As metrics for measuring Reliability, we have selected two associated with
the curation (addition of metadata coming from the literature) and the submis-
sion process. This tasks are key to ensure that the information stored in the
database are reliable and correct. Thus, we must check if the repositories pro-
vide mechanisms to control both processes, either manually or automatically.
In order to measure Currency, we have selected two metrics that check if the
link to the database is active and if the information is under review. The up-
date frequency varies depending on the database, from weeks to months. To be
sure that no relevant findings are missing due to the advances of the research,
we have considered that the database must be updated at least once a year.
Finally, being our purpose to assist the management of information by using
information systems, we prioritize those repositories that provide free access to
the information as well as mechanisms to ease the automation of common tasks
such as searching and downloading data.
The check of the above mentioned criteria have been added to the applica-
tion developed for the Search stage of the SILE method, enriching the decision
making process.
3.2.3 Data Quality Assessment of Genomic Information
Even when the genomic data sources with the highest quality have been selected,
not all the information they store are reliable enough to populate an information
system with the aim of supporting the genetic diagnosis process. The informa-
tion retrieved from each repository must be checked in order to assess the quality
and to avoid or minimize the consequences of using poor quality data. To this
aim, we apply the DQM to determine the criteria that the information must
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fulfill during the Identification stage of the SILE method.
We consider the genomic information as high-quality if at least there is
enough evidence to support the assertions, the information is standardized and
there is no conflicts among the different repositories. To this aim, the quality di-
mensions that are going to be measured are: Consistency and Reliability.
Table 3.4: Metrics and criteria of acceptance for the assessment of genomic
information.
Dimension Metric Criteria of acceptance
Consistency M1: Absence of conflicts
There must not be conflicts among databases in the
clinical interpretation of each variant.
There must not be conflicts among databases related
to the structural characteristics of a variant.
Reliability
M2: Assertion Reliability The relationship between the variant and the disease
must be associated to at least one published, peer-
reviewed paper with free access.
M3: Assertion Validity The reported consequences of a variant must have
been independently replicated by at least one group
besides the first group reporting the finding.
M4: Statistical Relevance
The published studies must have at least 700 partici-
pants and be replicated.
For pathogenic variants, the Odds Ratio must be
greater than 1.
For protective variants the Odds Ratio must be less
than 1.
For Genome Wide Association Studies (GWAS), the
p-value must be less than 5x10−8.
The next step is to describe the metrics and the criteria of acceptance as has
been done for genomic repositories (see Table 3.4). In order to measure Consis-
tency, we have selected a set of metrics to check the conflicts that could arise
when integrating the information from different repositories. The most common
problems are i) discrepancies in the interpretation of the clinical significance of a
DNA variant due to the use of different assertion protocols, and ii) discrepancies
in the structural information such as location in the chromosome due to the use
of different reference sequences. Both issues must be carefully considered be-
cause they can lead to erroneous results when searching for clinically important
variants.
The reliability of the relationship between the DNA variant and the disease is
measured according to the associated literature that corroborates the assertion.
To this aim, it is important to identify which type of studies can be performed
and which ones are useful for the task at hand.
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3.2.3.1 Types of Genetic Studies
There are different types of studies that can be performed to identify the ge-
netic causes of a disease. Each type of study has different purposes, as well
as advantages and disadvantages that must be carefully considered in order to
determine its relevance depending on the task to be performed. The genetic
studies can be classified as:
• Linkage studies: Genetic linkage is based on the tendency of DNA se-
quences that are physically close on a chromosome to be inherited together.
These studies are a powerful tool to identify the genes of interest for the
development of the disease through the study of different biological mark-
ers that appear in families with several affected members. It is common
to perform these studies over large families, but even when they are use-
ful to identify interesting regions in the human genome, they have a low
resolution [53].
• Association studies: The aim of these studies is to identify with pre-
cision the DNA variants in the genes that are responsible of causing the
disease in a population. The association studies require to sequence a con-
crete part of the DNA in a group of affected and healthy people. Then,
the frequencies of appearance of the different variants are compared to
identify those that are more frequent in the affected group. The limita-
tion of these studies is that they require to previously know the candidate
genes to study [54]. There are two types of association studies:
– Genome Wide Association Studies (GWAS): These are a par-
ticular type of association studies where all the variants present in the
genome are sequenced, increasing the probability of finding the genes
that cause the disease. These studies do not require to previously
know the candidate gene because the entire genome is sequenced,
but they have a higher probability of having false positives. To min-
imize this effect, it is required to have a huge number of participants
in the study and sctrict statistical thresholds [55].
– Cohort studies: A cohort is a subset of a population that may or
may not be exposed to factors that can influence the probability of
the occurrence of a particular disease. The cohorts are studied to
determine distinguishing characteristics, frequently associated to the
influence of the environment, drugs or specific medical treatments
[56].
The relevance of each type o study depends on the task to be performed.
For example, for exploratory analysis about the influence of genetics in the
development of a disease linkage studies are the right ones. But, if we already
know that the disease has a genetic basis and we need to specifically identify
the variants that causes it, we must focus on association studies. This reduces
the amount of information to be managed.
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Once the type of studies to consider are established, we must determine if
they are statistically relevant to support the assertion about the association
between the variant and the disease.
3.2.3.2 Statistical Relevance of Genetic Studies
Among the quality criteria established to measure the statistical evidence of
a study, the most widely used are the Odds Ratio (OR) and the sample size.
A sample size with sufficient statistical power is critical to the success of ge-
netic association studies to detect causal genes of human complex diseases. A
large sample size is more representative of the population, limiting the influ-
ence of outliers or extreme observations [57]. A sufficiently large sample size
is also necessary to produce results among variables that are significantly diffe-
rent. Following the practices of genetic diagnosis providers such as 23&Me or
Promethease, and the recommendations of the stakeholders, we established the
minimum sample size for genome association studies in 700 participants.
Odds ratios are used to compare the relative odds of the occurrence of the
outcome of interest (e.g. disease or disorder), given exposure to the variable of
interest (e.g. health characteristic, aspect of medical history) [58]. The odds
ratio can also be used to determine whether a particular exposure is a risk factor
for a particular outcome, and to compare the magnitude of various risk factors
for that outcome:
• OR=1 Exposure does not affect odds of outcome
• OR>1 Exposure associated with higher odds of outcome
• OR<1 Exposure associated with lower odds of outcome
The Interval of Confidence (IC) is used in conjunction with the OR to de-
termine the probability that the value falls within two values. To assure that
the OR is reliable, the lower or the upper limit of the IC must be consistent
with the calculated odds of the outcome (lower limit >1 for higher risk and
upper limit <1 for lower risk). The p-value is critical to control the number of
false-positive associations and the threshold of 5x10−8 has become a standard
for genome-wide association studies (GWAS) [59]. For the rest of case studies,
the p-value must be <0.0001.
The application of the above mentioned criteria ensures that the informa-
tion stored in the database during the Load stage of the SILE method is of
enough quality to extract reliable and meaningful conclusions in the Exploita-
tion stage.
3.3 Conclusions
Throughout this chapter, we have described a method to manage genomic infor-
mation in an efficient way, with the aim of populating a GeIS with high-quality
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data. To accomplish this task we have tackled 3 design problems:
• How can the most suitable genomic data sources be found (RQ3)?
• How can the relevant information be identified (RQ4)?
• How can the information be structured and stored for its further exploita-
tion (RQ5)?
The SILE method comprises 4 systematic stages (Search, Identification,
Load and Exploitation) and uses the CSHG as the conceptual structure re-
quired to harmonize the information under a holistic perspective. The aim of
the Search stage is to identify the genetic repositories that store the informa-
tion required to succeed in fulfilling the goals of a defined task. During the
Identification stage, the information from the different sources is harmonized
into a common data model so it could be loaded into a database for its further
exploitation. It requires to describe in detail the different options to access the
repositories and the set of transformations to represent the information accor-
ding to the structure of the CSHG. The aim of the Load stage is to convert
the raw data coming from the genomic repositories into a queryable format and
ensure the persistency of the information. Finally, the aim of the Exploitation
stage is to extract knowledge from the information stored in the database. As
an example, a tool called VarSearch has been developed to provide support to
the genomic diagnosis by identifying potentially damaging variants in the DNA
of a patient, according to the information stored in the database.
The genomic domain is under constant evolution so the repositories and
the stored information can become obsolete quickly. Furthermore, genomic
information is susceptible of containing errors or be inaccurate. Thus, two new
design problems arise:
• Which are the criteria that genomic information must fulfill to ensure its
quality (RQ6)?
• How can the quality of genomic information be measured (RQ7)?
We have addressed these problems by defining a DQM, specially designed for
genomic information. The aim of the methodology is to ensure Veracity through
the selection of high-quality repositories, and provide Value by extracting the
highest quality data from each one. The DQM has been connected with the
Search and Identification stages of the SILE method. This ensures that the
information stored in the database during the Load stage and the results derived





In chapter 3, a method to manage genomic data in an efficient way was intro-
duced and in this chapter we discuss its validity in terms of the contribution
to fulfill the stakeholders goals. To this aim, we work toward answering the
following research questions:
• To which extent are the results of our method accurate and valid? (RQ8).
• Do domain experts think that our method is useful to manage genomic
information? (RQ9).
In order to validate the accuracy of the method and its usefulness, we have
been working with a company specialized in generating personal genome re-
ports. In this real, industrial working context we head to two experts in genetic
diagnosis (a geneticist and a clinician) that were responsible of the correspond-
ing teams in charge of finding and selecting relevant DNA variants, and we
performed four different case studies: two initial cases and two complementary
cases. The aim of the first initial case study was to compare the results obtained
by using the method with the results obtained by the group of experts in the
search of the genetic causes of an already studied disease (migraine), in order
to validate the accuracy of the results. The aim of the second initial case study
was to use the method to search for the genetic causes of a disease (epilepsy),
currently under study and particularly difficult because of the complexity of the
disease context, so we can measure the usefulness of the method to guide the
research process. After performing these two initial case studies, two more were
faced (Crohn’s disease and male breast cancer) in order to reinforce the idea
of generalization of the SILE method to any kind of phenotype. Our final goal
was to provide a solution that could be used to systematize the management of
relevant variants for a full-coverage genomic diagnosis.
In order to test the method for these four case studies, we developed the
GeIS that would support the different stages of the process. The details about
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the development of the GeIS are described in section 4.1. Along sections 4.2,
4.3 and 4.4, we describe the execution of the method for the case studies and
detail the results. Finally, we draw conclusions in section 4.5.
4.1 Building a Genomic Information System
The task to be performed for the validation is the identification of the DNA vari-
ants related with the risk of suffering four different diseases: migraine, epilepsy,
Crohn and male breast cancer.
The first step to build the GeIS that supports the process was to define the
ontological background required to represent the information under a holistic
perspective. Using the CSHG as basis, we have determined the view that would















































































































Figure 4.1: Conceptual schema used to design the GeIS.
The main entities of the conceptual schema are Variation and Gene. The
Variation1 entity represents the changes in the DNA that are considered to be
1The terms Variation and Variant are frequently used as synonyms by the genomic reposito-
ries. Along this thesis we have used the term Variant due to its increasing use. Nevertheless,
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the cause of the disease (phenotype) of interest. There are different types of
variants, depending on the frequency of appearance in a certain population and
the precision of the information associated to them. The notion of SNP is asso-
ciated to its frequency of appearance in a certain population and the amount of
information about the combination of alleles that the individual carries, known
as genotype. According to the frequency of appearance the variants can be:
Mutations, if the frequency is lower than 1%, and Single Nucleotide Polymor-
phisms (SNP) or Copy Number Variations (CNV) if the frequency is greater
or equal to 1%. A SNP is a change that affects a short region of the genome,
usually a single letter change. A CNV is a phenomenon in which a section of
the genome is repeated [60]. The number of repeats varies between individuals
and affects a considerable number of nucleotides. According to the precision
of the information there are Precise variants, which change and position in the
DNA sequence are known, and Imprecise variants, which position and change
are not known. Precise variants can be Insertions, Deletions, Indels and Inver-
sions. The association of a variant with the development of a disease must be
supported by the literature and the statistical evidence.
The Gene entity represents the elements which alteration derives in a mal-
function that leads to the development of the disease. In addition, the GeIS
must store the information associated to the databases where the information
has been extracted from to ensure the traceability of the information and help
to keep the information updated. A complete description of each attribute of
the conceptual schema can be seen in Annex A.
Once the conceptual schema was determined, we started the development of
the GeIS to support the four stages of the SILE method: Search, Identification,
Load and Exploitation.
4.1.1 Searching for Genomic Data Sources
The first stage of the SILE method requires the support to the search of the
most adequate data sources to solve the task at hand. To this end, we used
the tool described in Section 3.1.1 in order to extract an initial set of useful
data sources. Doing this, the noise produced by the great amount of available
repositories is reduced, and this step helped us to focus on selecting those that
are reliable and useful enough.
As genomic repositories cover a wide range of species and experimental data,
we performed a search using the conceptual schema as a guide for the search. We
focused on databases that store genomic information about humans, germline
variants (those that are inherited from parent to child) and databases that
do not result of gathering the information from other sources (e.g. GenesCards
comprises information from other sources such as HGNC and Entrez Gene so we
prefer to head to the original sources). At the end of the search, we identified
The CSHG was built considering the term Variation. As there is not consensus or formal
recommendations about it, we will use both terms as synonyms from now on.
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9 repositories that can be used to extract the information: PubMed, NCBI
Assembly, GWAS Catalog, ClinVar, Ensembl, dbSNP, HGNC, Entrez Gene and
1000 Genomes. A brief description of their main characteristics is introduced
below.
PubMed2 is a resource that is developed and maintained by the National
Center for Biotechnology Information (NCBI), at the U.S. National Library
of Medicine (NLM). The data source comprises over 29 million citations and
abstracts for biomedical literature, life science journals, as well as behavioral
sciences, chemical sciences, and bioengineering [61].
NCBI Assembly3 is a database that provides information on the structure
of assembled genomes, assembly names and other meta-data, statistical reports,
and links to genomic sequence data [62].
GWAS Catalog4 is a publicly available, manually curated resource of all
published genome wide association studies, collaboratively produced and develo-
ped by the National Human Genome Research Institute (NHGRI) and the Euro-
pean Bioinformatics Institute (EMBL-EBI). They curate eligible studies within
1-2 months of publication, dependent on the availability of literature, and the
data is released on a weekly cycle.
ClinVar5 is a public archive of relationships among human variants and
phenotypes, with supporting evidence [63]. The database has been developed
by the NCBI.
The Ensembl Variation6 database stores information about variants and,
where available, associated disease and phenotype information. The database
has been developed as a joint project between EMBL-EBI and the Wellcome
Trust Sanger Institute and is updated approximately five times each year with
new genome assemblies and additional data as it becomes available [64].
dbSNP7 is a repository for both single base nucleotide substitutions and
short deletion and insertion polymorphisms. The database has been developed
in collaboration with the NHGRI and the NCBI [65].
The HUGO Gene Nomenclature Committee8 database is a curated
online repository that stores information about approved gene nomenclature,
gene groups and associated resources including links to genomic, proteomic and
phenotypic information.
Entrez Gene9 is a NCBI’s database for gene-specific information. The
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have an active research community or that are scheduled for intense sequence
analysis [66].
The 1000 Genomes Project10 is the largest public catalogue of human
variant and genotype data. The goal of the 1000 Genomes Project is to provide a
resource of almost all variants, including polymorphisms and structural variants,

















Figure 4.2: Data sources coverage according to the CSHG.
As can be seen in Figure 4.2, the initial set of genomic repositories covers
different parts of the conceptual schema. The structural part is covered by
HGNC, Entrez Gene and Assembly, that provide information about the loca-
tion of the variants in the DNA sequence. The bibliography that supports the
assertion among the variants and the studied disease is provided by PubMed.
The specific information about the variants is covered by the GWAS Catalog,
ClinVar and Ensembl. More details are provided by dbSNP, which focuses on
a specific type of variants (polymorphisms), and 1000 Genomes that provides
information about their frequency of appearance in diverse populations.
In addition, the databases conform the quality criteria established in section
10www.internationalgenome.org/
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3.2.2: the stored information are manually curated by experts, the submission
process has enough quality controls to ensure the correctness, the databases are
active and updated as well as they provide mechanisms to extract the informa-
tion.
Besides the databases mentioned above, we found one repository specific for
genomic variants associated with the epilepsy disease: The Lafora Database.
Nevertheless, this database is not currently maintained so the information is
not reviewed or updated, which does not conform with our quality criteria.
Therefore, the Lafora Database has not been selected as a valid source.
Considering the dynamism of the selection process that we are describing,
the use of this approach and the search tool developed to assist the process,
the information system can be easily extended by adding new sources at any
moment, as long as they meet the quality requirements.
4.1.2 Identifying Relevant Information
The second stage of the SILE method consists in the identification of the relevant
information from each data source. To this aim, the GeIS must support the
extraction of the information from the repositories, the integration following
the structure provided by the conceptual schema, and its analysis according to
the quality criteria established in Section 3.2.3. The core of this part of the
GeIS follows an Extraction-Transformation-Load architecture as can be seen in
Figure 4.3.
Figure 4.3: Architecture to support the SILE method.
4.1.2.1 The Extraction Module
The first step to extract the information from each data source is to determine
the mechanisms that they provide to access the stored data, and select the most
adequate according to our needs. In our case, we have selected as first choice
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the mechanisms that allow a high level of automation, such as REST services.
In Table 4.1, the names of the REST services selected to access each data source
are described.
Table 4.1: Types of access used to extract the information from the databases.
Data Source Access Name Access Type
PubMed E-Utilities RESTful
NCBI Assembly E-Utilities RESTful





Entrez Gene E-Utilities RESTful
1000 Genomes Biomart RESTful
The REST service used to access the databases provided by the NCBI
(PubMed, Assembly, ClinVar, dbSNP and Genes) is called E-utilities. It is
a set of server-side programs that provide a stable interface to search for and
retrieve data from 38 databases, covering a variety of biomedical data [68]. An-
other REST service used is Biomart, a data-mining tool that provides access
to the databases that the Ensembl project comprises (Ensembl Genes, Ensembl
Variation, Ensembl Regulation and Vega) [69]. In our case, Biomart is used
to extract information from Ensembl Variation, that includes information from
1000 Genomes too. HGNC provides a way of searching and fetching data from
the database within a script/program called genenames.org. Using this REST
web-service we can get the information from the database either in XML and
JSON format [70]. Finally, the information from the GWAS Catalog is ex-
tracted through the REST service in Hypertex Application Language (HAL)
format.
Once the mechanisms to access the repositories are established, the next
step is to implement the connectors that will extract the data. To this end we
need to define a set of mapping rules. For illustration purposes, in Table 4.2 we
provide some of the mappings related with the Variation entity.
Each mapping rule is a logic formula with variables in its left end side
that are computed from the variables in its right end side. As an example,
the entity Variation of the CSHG is filled with data from the GWAS Catalog
database, together with data from ClinVar, Ensembl and dbSNP. According to
the CSHG, a variation is represented by three attributes (db variation id, clin-
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Table 4.2: Examples of mapping rules.
Variation(db variation id,-,-) ⊇ GWAS(tr(SNP ID CURRENT))
Variation(db variation id,-,-) ⊇ ClinVar.variation(tr(db id))
Variation(-, clinically importance,-) ⊇ ClinVar.clinical significance(description)
Variation(db variation id, clinically importance,-) ⊇ Ensembl(refsnp id,clinical significance)
Variation(db variation id, clinically importance, other identifiers) ⊇ dbSNP(SNP ID, CLINICAL SIGNIFICANCE, DOCSUM)
ically importance and other identifiers). The attribute db variation id can be
extracted from GWAS, ClinVar, Ensembl and dbSNP. Both GWAS and Clin-
Var require the transformation of the raw data to meet the required format.
The attribute clinically importance is provided by ClinVar and Ensembl, and
the information associated to the attribute other identifiers is provided by the
attribute DOCSUM of dbSNP. All the required mapping rules to build the GeIS
are described in Annex B.
The connection modules to the selected databases and the information ex-
traction procedures have been implemented with R (using the Rentrez and
BiomaRt libraries) as well as Python scripts. The reason why these program-
ming languages have been selected is that they are widely used by the Bioin-
formatics Community and many libraries and documentation can be found on
the web. To help the user to query and extract the information from each data
source a graphical interface has been built (see Figure 4.4).
Figure 4.4: Graphical User Interface for data extraction.
The user can selet the database to be queried in the drop down menu on the
left, and specify a key term for the search (in this case a phenotype). He can
also specified the number of records to be retrieved from the repository. The
results of the search are grouped in 4 different tabs:
• Variant Data: Contains information about the DNA variants retrieved.
• Bibliography: Contains informacion about the associated bibliography.
• Structural informacion: Contains information about the location of the
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variants in the genome.
• Associated phenotypes: Contains information about all the phenotypes
associated to the variants.
The information retrieved can be downloaded into a CSV file specified by
the user. In addition, the user can upload and view any CSV file that has been
previously created using the ”Select CSV file” dialog on the right side.
The extracted data are stored into a temporary relational database from
which it is transformed and checked.
4.1.2.2 The Transformation Module
The Transformation module is responsible of transforming and integrating the
data into a common structure. Some of the attributes are acquired exactly
as they are in the original source, others need the application of transforma-
tions (denoted as tr in the mapping specifications), and others are computed
as a combination of multiple source fields (denoted as comb in the mapping
specifications). These transformations are specified in a set of transformation
rules. As an example, the format of the attribute Variation.db variation id
comprises the rs prefix followed by an integer number. As the variant identifier
coming from the GWAS Catalog is represented only by the integer number, it
requires the addition of the rs prefix. The set of all the transformation rules
required to transform the raw data into the correct format is summarized in
Table 4.3.
Table 4.3: Transformation Rules
Database Name Action
PubMed tr(PubDate) Extract Year
GWAS tr(REPLICATION SAMPLE SIZE) NA = NO: YES
GWAS tr(STRONGEST SNP-RISK ALLELE) Extract risk allele
GWAS tr(SNP ID CURRENT) Add prefix: ’rs’
ClinVar tr(db id) Add prefix: ’rs’
ClinVar tr(variant type) See Annex C
1000 Genomes tr(population) Extract population name
dbSNP tr(SNP ID) Add prefix: ’rs’
dbSNP tr(DOCSUM) Extract NG Identifier
dbSNP tr(DOCSUM) Extract NC Identifier
dbSNP tr(CHRPOS) Extract Position
As we already discussed in Section 3.1.2, it is also required to define a shared
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set of homogenized values for those attributes that use different ontologies to
represent the stored values. In this case, the type of the DNA variants which
correspondences with the conceptual schema can be seen in Annex C.
The integration and transformation processes require following a number of
consecutive steps:
• Data Processing: Involves cleaning the extracted data as well as con-
verting all the values to the required data types.
• Data Transformation: Involves the implementation of the transforma-
tion rules required to represent the information coming from the different
repositories into a common structure.
• Data Integration: Involves the consolidation of the data under a single
unified view.
• Data Deduplication: Involves removing duplicate copies of repeating
data.
The transformation rules for each data source and the integration process
have been implemented using Pentaho’s Data Integration11 (Kettle), because it
is a flexible and complete ETL tool, freely accessible. In Figure 4.5, a simplified
view of the Kettle transformation and integration entities can be seen.
Figure 4.5: Simplified view of the transformation and integration processes
performed with Kettle.
The first part of the pipeline takes the information from the different reposi-
tories (ClinVar, Ensembl and GWAS) and prepares the data for the integration,
harmonizing and formating the different columns of each data source. Then,
the transformed data is sorted by variant identifier and combined into a com-
mon dataset. During the final stage of the pipeline, the values of the common
columns are merged and the results are stored in a CSV file.
Once the transformation and the integration processes are finished, the data
are ready to perform the last step in the identification of relevant information:
11https://community.hitachivantara.com/docs/DOC-1009855-data-integration-kettle
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the quality assessment. As has been explained in Section 3.2, not all the infor-
mation coming from the repositories are reliable enough to perform a genetic
diagnosis so it is important to measure its quality in order to ensure that only
the information with the highest quality is considered. To this aim we have im-
plemented the quality criteria explained in section 3.2.3 as a new set of Kettle
transformations.
In order to optimize the quality assessment, the different criteria are applied
following the workflow described in Figure 4.6.
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Figure 4.6: Data Quality Workflow.
One of the quality criteria specified in the workflow requires to determine the
relevancy of the associated bibliography. As has been seen in Section 3.2.3.1,
the first step to determine if a study is relevant is to identify its type. This is
an information that the databases do not provide so, a relevant question arises:
how can be the bibliography classified according to its type?
There are two ways to identify the articles according to its type: i) with the
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keywords defined by the authors and ii) using the MeSH terms associated to each
study. MeSH (Medical Subject Headings) is a thesaurus of controlled vocabulary
provided by the National Library of Medicine [71]. The terms provided by this
thesaurus are used to describe the content of each article and for indexing them
in the PubMed database. The MeSH terms required to classify the bibliography
associated to the DNA variants are described in Table 4.4.
Table 4.4: MeSH terms used to classify the bibliography by type.






Genetic Association Studies (D056726)
GWAS Studies Genome-Wide Association Study (D055106)
Cohort Studies Cohort Studies (D015331)
Despite the wide use of the MeSH terms, not all the articles are fully de-
scribed and sometimes it is required to check the keywords provided by the
author or the abstract to complete the information. Figure 4.7 shows the work-
flow followed to classify the bibliography according to the different study types.
One or more labels will be assigned to each study according to the conditions
established for each type:
• In the case of the GWAS studies, it will first be determined if they come
from a GWAS source such as GWAS Catalog. If they do not, the MeSH
term Genome-Wide Association Study will be searched. In case the term
does not appear, the title, abstract and associated keywords will be re-
viewed in search of one of the following terms: genome-wide, genome wide,
whole-genome, whole genome and genomewide. If none of them indicates
that it is a GWAS study, the category OTHER will be considered.
• For association studies, the MeSH terms Case-Control Studies and Genetic
Association Studies will be searched. If they do not appear, the term case-
control will be searched in the abstract. If none of them indicates that the
study is of type ASSOCIATION, the category OTHER will be considered.
• For cohort studies, the MeSH term Cohort Studies will be searched. If it
does not appear, the category OTHER will be considered.
• For linkage studies, the MeSH terms Genetic Linkage and Linkage Dise-
quilibrium will be searched. It they do not appear, the category OTHER
will be considered.
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• If the article under review cannot be classified as any of the above men-
tioned types, it will be labelled as OTHER.
NO









































Figure 4.7: Workflow to classify bibliography according to the type of study.
Only those articles classified as Cohort Studies, Association Studies or GWAS
Studies are going to be considered as relevant to provide a genetic diagnosis.
Once these articles are identified, their statistical relevance can be measured as
well as the appearance of contradictory evidence.
Along the quality assessment, the DNA variants are classified in four main
groups:
• Variants Discarded: This group includes the variants which clinical
significance is not relevant for the task at hand (e.g. benign, likely benign,
uncertain, etc.). It also includes those variants without bibliography to
support the association with the disease of interest.
• Variants with contradictory evidence: This group includes the vari-
ants which associated studies are relevant but contain contradictory ev-
idence (e.g. one study considers the variant as pathogenic while other
considers the variant as benign), as well as those which clinical signifi-
cance has been proved to be contradictory in the ClinVar database.
• Variants without enough evidence provided: This group includes
the variants which associated studies are not replicated or not statistically
significant (i.e. not enough number of participants and OR, IC and p value
out of the minimum accepted requirements).
• Variants Accepted: This group includes the variants that have fulfilled
all the quality criteria and thus can be considered useful to provide a
genetic diagnosis.
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Finally, the accepted variants are classified according to the level of the evi-
dence provided. To this end, we check the number of associated studies and the
date on which the last study has been performed. If the variant has more than
two studies and less than three years have elapsed since the publication of the
last one, the evidence can be considered as Strong. Three years is considered
by experts time enough for new studies that contradict the evidence to appear.
If there is only one study but less than three years have elapsed since its pub-
lication, the evidence can be considered as Moderate. In any other case, the
evidence is considered as Limited. These criteria are based on the recommenda-
tions provided by the American College of Medical Genetics and Genomics and
the Association for Molecular Pathology [72].
At the end of the Identification stage, the information extracted from the ge-
nomic repositories has been harmonized into a common data model and checked
in order to determine its validity. Therefore,it is prepared to be stored ade-
quately to assure its persistency.
4.1.3 Information Storage
With the aim of preparing the information for its further exploitation, the GeIS
must support its storage in a target database that conforms the structure pro-
vided by the conceptual schema. To this aim, we have developed the Human
Genome Database (HGDB) which structure can be seen in Figure 4.8.
The HGDB is a relational database. We used this technology because it is
well-known and widely accepted, with a solid technological background, and it
provides an intuitive organization based on the table structure that is familiar
to most users and close to the way the concepts are represented in the CSHG.
These characteristics simplify the development and use of the database. In
addition, data integrity is an essential feature of the relational databases. They
provide strong data typing and validity checks as well as referential integrity,
which ensure the accuracy and consistency of the data. We are aware that
new technologies such as NoSQL databases have arisen and consequently, a
new research line is under development within our research group with the
aim of exploring these alternative database representations and compare how
efficient and effective they are. Even though in this PhD work we report a
relational-based implementation, the conceptual model-based strategy that we
use warranties a semantic independence between the conceptual level and the
logical level. This implies that changing the database model would preserve the
conceptual schema, and only the data transformations should be adapted to any
new, selected database model.
The storage of the information into the HGDB is performed by the Load
Module and requires to carry out the needed checks derived from the technology
used to build the database. Due to the HGDB is a relational database we must
avoid the unsuccessful load due to constraint violations or wrong data types.
To this aim, the checks to be performed are:
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Figure 4.8: The Human Genome Database.
• Attribute Value Constraints: Implies checking column data types and
not null constraints.
• Referential Integrity Constraints: Implies checking foreign key con-
straints.
• Key Constraints: Implies checking unique key constraints. Primary key
constraints can be implemented as a combination of a unique key rule and
not null rules of each column that is part of the primary key.
A new set of Kettle transformations were implemented in order to support
the check of the above mentioned constraints, as well as the final load of the
information in the HGDB. Once the load process is finished, the information
is ready for the Exploitation phase what can be performed by tools such as
VarSearch (described in Section 3.1.4).
The storage of the information is the last stage in the building of the GeIS
that provides support to the tasks to be performed for the validation of the
SILE method. In the next sections we expose the results of applying the SILE
method in the different case studies with the support of the GeIS.
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4.2 The Migraine Case
The aim of this case study is to determine the accuracy of the results provided
by the SILE method by comparing them with those manually obtained by the
stakeholders in a previous research. The task to be performed is the identifica-
tion of the DNA variants associated to the risk of suffering migraine, in order
to perform a genetic diagnosis from a patient sample.
As the most prevalent and disabling neurological disorder, migraine affects
the lives of millions of people worldwide, and for many there are still no effec-
tive treatments [73]. Migraine attacks cause severe throbbing pain or a pulsing
sensation, usually on just one side of the head. It is often accompanied by
nausea, vomiting, and extreme sensitivity to light and sound. They can cause
significant pain for hours to days and can be so severe that the pain is disabling.
The genetic causes associated to migraine are being studied by looking at the
DNA of large families where migraine is passed down at every generation [74].
In recent years, it has become very clear that migraine is mainly a disorder of
the nervous system and significant progress has been made in the understand-
ing of the causes as well as new ideas for treatments have arisen. This is an
important step in working out why some people are predisposed to suffering this
condition.
The accuracy of the SILE method in this case study is measured by determin-
ing the presence of false positives (variants incorrectly considered as relevant)
and false negatives (variants incorrectly considered as irrelevant) in the results
that pass all the quality criteria that have been established. False positive re-
sults have a negative impact due to they increase the amount of information to
be reviewed by the experts and consequently it leads to a loss of confidence in
its usefulness. Furthermore, they could have a direct impact in the health of the
patients whom could undergo unnecessary treatment or take unnecessary drugs.
On the other hand, having false negatives could imply the loss of information
that could delay the diagnosis and treatment of the disease.
To test the accuracy of the SILE method, the first step is to extract, trans-
form and integrate the information coming from the genomic repositories that
have been selected as relevant. The number of variants extracted vary from
one genomic repository to another (174 from Ensembl, 351 from ClinVar and
203 from GWAS Catalog). This is due to the scope of the repositories. While
ClinVar stores information about different types of variants (SNPs, insertions,
deletions, etc.), Ensembl stores information about SNPs and GWAS focuses on
GWAS studies.
The information about the DNA variants must be integrated with the asso-
ciated bibliography (219 articles from PubMed) and the structural information
about the genes affected by the DNA changes (385 genes from HGNC and Entrez
Gene), as can be seen in Figure 4.9.
Most of the variants are SNPs so extra information must be added from the





















Figure 4.9: Extraction and integration of the DNA variants associated with
migraine.
dbSNP repository. The reported studies associated to the variants have been
performed over three main populations (European, Han Chinese and Dutch)
and the location of each variant are expressed according to two different ref-
erence sequences or assemblies: GRCh38 and GRCh37. All the extracted in-
formation went through the transformation and integration process described
in Section 4.1.2 and after removing duplicates, 673 unique DNA variants were
collected.
If we look at the common information among the data sources, only 55 vari-
ants are present both in ClinVar and Ensembl (see Figure 4.10). Furthermore,
there are not variants present in the three repositories, what justifies the impor-
tance of considering as much sources as possible when performing the research
to ensure the completeness of the information. The omission of any of the se-
lected sources could lead in the loss of hundreds of potentially valid variants as
well as the loss of information crucial for the research process.
Once the information has been extracted and integrated, it is ready to per-
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Figure 4.10: Common results among databases in the migraine case study.
form the quality assessment in order to determine which variants are relevant
enough to be used in a genetic diagnosis. In Figure 4.11, the evolution of the
results along the quality process are shown. Using as starting data set the
673 variants determined in the previous phase, the different metrics are sys-
tematically applied in order to classify the results according to their level of
relevance:
• Variants discarded: about the 3% of the variants are discarded because
the clinical significance is not relevant for the task at hand (i.e. benign,
likely benign, uncertain and likely pathogenic). Attending to the associ-
ated evidence, about 54% of the variants have been discarded due to there
is not bibliography to support their connection with the disease.
• Variants with contradictory evidence: about 5% of the variants are
discarded due to conflicts in the interpretation of the clinical significance
(e.g. one submitter considers the variant as benign and another one con-
siders the variant as pathogenic).
• Variants without enough evidence provided: the 30% of the variants
are discarded because the associated studies are not statistically signifi-
cant. Nevertheless, not all the databases provide this information so the
GeIS returns an additional result: a list with 49 variants that require a
manual review of the associated bibliography.
• Variants accepted: only 4 variants pass all the established criteria and
thus are considered as relevant.
The number of variants to be manually reviewed (491) is considerable lower
than the number of variants present in the initial dataset (673), as well as the
effort that the revision implies. In Table 4.5, a summary of the variants selected
as relevant by the GeIS is shown.
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Figure 4.11: Quality assessment results for migraine case study.
Due to only one article is associated to each variant and more than 3 years
have lasted since they have been published, the evidence can be considered as
Limited. This means that although the increasing number of studies, there are
not sound results yet and the conclusions derived from the genetic diagnosis
must be carefully considered.
4.3 The Epilepsy Case
The aim of the second case study is to determine if the SILE method is useful
to manage the genomic information in a particularly difficult disease context,
the epilepsy. The task to be performed is the same as for the first case study:
to determine the DNA variants associated to the risk of suffering the disease.
Nevertheless, epilepsy is a spectrum condition with a wide range of seizure types
56 CHAPTER 4. TREATMENT VALIDATION
Table 4.5: Variants associated with the risk of suffering migraine.
ID Gene Chromosome Clinical Significance Bib. ID/Year
rs10166942 TRPM8 2 Risk Factor 21666692 (2011)
Clinvar:12388 TNF 6 Risk Factor 14718719 (2004)
rs1835740 LOC 101927066 8 Risk Factor 20802479 (2010)
rs2651899 PRDM16 1 Risk Factor 21666692 (2011)
what makes the gathering and analysis of the genetic information a challenge
[75]. Furthermore, epilepsy means the same thing as “seizure disorders” and
the word “epilepsy” does not indicate anything about the cause of the per-
son’s seizures or their severity. Many people with epilepsy have more than one
type of seizure and may have other symptoms of neurological problems as well,
which can be defined as an epilepsy syndrome. In addition, most individuals
with genetically determined epilepsy are thought to have a polygenic basis in
which multiple genes of low-to-moderate risk interact, sometimes with an envi-
ronmental contribution, to produce the epileptic disease [76]. Thus, in order to
provide an accurate genetic diagnosis it is crucial to manage as much informa-
tion as possible, which is a time consuming task for researchers. To this aim, we
validate the usefulness of the SILE method to collect and manage the genomic
information associated to epilepsy in terms of time saving and support to the
research process.
Table 4.6: Number of variants associated with the risk of suffering epilepsy
(grouped by keyword).
Epilepsy Seizures Lafora Unique Variants
ClinVar 6,932 6,238 78 11,243
Ensembl 4,632 1,252 4 5,111
GWAS Catalog 61 7 0 68
Unique Variants 7,224 6,200 76 11,506
The first step is to extract, transform and collect all the information associ-
ated to the keywords “epilepsy”, “seizures” and “Lafora” (a type of progessive
myoclonic epilepsy). As can be seen in Table 4.6, the number of DNA variants
collected (11,506) are considerable higher than those obtained for the first case
study (673), which gives an idea of the complexity of the disease context.
For each row and column, the table shows the number of unique results, due
to the same variant can be stored in more than one database or belong to more
than one type of epilepsy. As a result, the total number of DNA variants to be
analyzed is 11,506. The information about the DNA variants must be integrated
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with the associated bibliography (844 articles from PubMed) and the structural





















Figure 4.12: Extraction and integration of the DNA variants associated with
epilepsy.
From the total amount of variants, 8,200 are SNPs so extra information must
be added from the dbSNP repository. The reported studies associated to the
variants have been performed over 4 main populations (European, Han Chinese,
African American and Korean). As in the migraine case study, the location
of each variant is expressed according to two different reference sequences or
assemblies: GRCh38 and GRCh37.
Once the integration process is finished, the information is ready to perform
the quality assessment which process can be seen in Figure 4.13.
At the end of the process, the variants are classified according to their rele-
vance for the task at hand:
• Variants discarded: about the 11% of the variants are discarded due to
the clinical significance is not relevant (benign, uncertain, etc.). It is very
significant that almost 64% of the variants are discarded due to they do
not have associated bibliography.
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Figure 4.13: Quality assessment results for the epilepsy case study.
• Variants with contradictory evidence: over 7% of the variants are
discarded due to conflicts in the interpretation of the clinical significance
(e.g. one submitter considers the variant as benign and another one con-
siders the variant as pathogenic).
• Variants without enough evidence provided: about 16% of the vari-
ants variants are discarded due to the associated studies are not statisti-
cally significant. In addition, 129 variants require a manual review due
to the information needed to perform the analysis is not provided by the
repositories.
• Variants accepted: finally, 32 variants have pass all the quality criteria
and thus they are considered as relevant. In Annex D, a summary of the
selected variants is shown.
As happened in the first case study, the SILE method results in a substantial
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time saving considering the initial amount of variants extracted from the sources.
Due to only one article is associated to each variant and more than 3 years have
lasted since they have been published, the evidence is considered as Limited.
The results are consistent with the existent knowledge about the disease. The
complexity of the biological mechanisms that causes the epilepsy as well as
the difficulty in its classification hinder the process of identification of relevant
information if it has to be performed manually. Nevertheless, with the SILE
method we were able to differentiate those variants that can be considered as
relevant among the huge amount of available information.
Comparing the results obtained in both case studies, we can see the impor-
tance of providing methods to measure the quality of the information in fields
were the knowledge is evolving at a fast pace. As can be seen in Table 4.7,
less than 1% of the initial variants for both case studies can be considered as
relevant.
Table 4.7: Comparison of results between both case studies.
Migraine Epilepsy
Discarded 57% 75%
Contradictory evidence 5% 7%
Not enough evidence 30% 16%
Manual review 7% 1%
Accepted 1% <1%
By identifying the information that it is not relevant (at this moment),
we can decrease the amount of time required to analyze the evidence that is
valuable and we can help the stakeholders to focus only on those that can
provide new meaningful insights about the area of study. In the next section
we are going to discuss the results obtained in terms of validity and usefulness
for the stakeholders.
4.4 Results
In order to answer the research questions mentioned at the beginning of this
chapter, the results of both case studies have been presented to two experts
in genetic diagnosis (a geneticist and a clinician), that lead the team on ap-
plied genomics in a company dedicated to the genomic diagnosis in a context of
industrial Medicine of Precision.
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4.4.1 Migraine Case Study Results
The aim of the first case study was to answer the RQ9: To which extent are the
results of our method accurate and valid?
The accuracy of the SILE method was measured by determining the pre-
sence of false positives (variants incorrectly considered as relevant) and false
negatives (variants incorrectly considered as irrelevant). After the analysis of
the results and the comparison with those obtained by the stakeholders, the
results were:
• Number of false positives: 1
• Number of false negatives: 0
• Number of new findings: 1
• Number of results in line with current research: 2 (100%)
According to these results, all the relevant variants have been identified
which is one of the main concerns when dealing with information with the aim
of providing a genetic diagnosis. Furthermore, one relevant variant that the
stakeholders did not considered has been found. As a consequence, it is going
to be included in their catalog of variants to be checked for this disease.
According to the variant classified as false positive (rs1835740), a new dis-
cussion has been opened. The cause why the stakeholders discarded the variant
as relevant was because there is one study that has not found association be-
tween the variant and the disease in the Spanish population [77]. As we are not
focusing on any specific population, we cannot discard the variant, that has been
proved to be relevant in other populations such as Finland, The Netherlands,
Germany and Denmark [78]. Due to the discrepancies among populations must
be carefully studied to provide new insights about the disease, the identification
of these cases is going to be considered in a future version of the information
system. Overall, the results obtained by applying the SILE method have been
considered as accurate by the stakeholders.
4.4.2 Epilepsy Case Study Results
The aim of the second case study was to answer the RQ10: Do domain experts
think that our method is useful to manage genomic information?
The method is considered useful if it can help the researchers in the identifi-
cation of potentially relevant biomarkers for the diagnosis of a complex disease
such as epilepsy, whose analysis is still under open investigation and it is not
yet included in their catalog of selected phenotypes. From the initial dataset of
11,243 variants, only 32 have been considered as relevant. After the analysis of
the results, the conclusions are:
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• Number of results in line with the current research: 15 (100 %)
• Number of new findings: 6
• Number of potentially significant biomarkers: 11
According to these results, the stakeholders have considered the method as
useful due to 15 variants are in line with the current results obtained by them.
Furthermore, 6 variants that they have not found are going to be added to the
catalog of variants to be checked for the disease. Due to the complexity of the
information to be managed, the stakeholders had to reduce the research and
focuse only on a few types of epilepsy. With the SILE method we were able to
handle the data associated to a higher amount of epilepsy types and as a result,
11 variants were considered as potentially significant for a further increase in
the coverage of the genetic service provided by the stakeholders.
4.4.3 Complementary Case Studies
The good results obtained in the validation has pushed us to start a generic
validation to analyze in depth the particularities of the method when applied
to different phenotypes. Our final goal is to make SILE become a fundamen-
tal method to manage genome data providing the right, valuable contents to
the most advanced Genome Information Systems. To this aim, we report here
the results of the last two applications of the method that have been done at
the request of the stakeholders with the aim of corroborate its value in differ-
ent scenarios. The selected phenotypes were Crohn disease and male breast
cancer.
4.4.3.1 Crohn Disease Case Study
Crohn disease, also known as inflamatory bowel disease type 1, is a chronic
disorder that involves an abnormal funtion of the immune system which causes
inflammation in the digestive system [79]. The causes of Crohn results from
a combination of genetic, environmental and lifestyle factors. Even when the
inheritance pattern of this disease is unclear, it is known that about 15% of
affected people have a first-degree relative with the disorder [80]. The under-
standing of Crohn’s disease is in an early stage and the identification of relavant
DNA variants is useful to provide insights into disease biology and potential
therapeutic targets.
As can be seen in Figure 4.14, the number of variants initially extracted from
the genomic repositories is 739. There is a huge amount of bibliography (2,976
articles) about studies performed over 120 genes and 6 populations (European,
Japanese, Jewish, Korean, Polish and Southern European).
Despite the evidence provided, how many variants can be considered as
relevant for the genetic diagnosis? To answer this question, we performed the
data quality assessment which results can be seen in Figure 4.15.





















Figure 4.14: Extraction and integration of the DNA variants associated with
Crohn disease.
From the initial amount of 739 DNA variants and 2976 articles, only 29
variants and 25 articles can be considered as relevant to perform a genetic di-
agnosis. Over 37% variants were discarded because they do not have a relevant
clinical significance or associated bibliography. Over 57% of the variants were
discarded due to the studies performed were not statistically relevant enough.
Only 5 variants required manual review because the information needed to per-
form the analysis was not provided. After the manual review, none of them
was considered as relevant. One of the variants included in the final results
(rs2241880) has a moderate level of evidence because there is one study per-
formed less than three years ago (2016). The rest of variants have a limited
level of evidence. A summary of the information associated to the variants
found can be seen in Annex E.
4.4.3.2 Male Breast Cancer Case Study
Less than 1% of all breast cancers occur in men, what makes it a rare disease.
As a consequence, few cases are available to study so the population samples
used in the studies are very small. Nevertheless, when a number of these small
studies are grouped together, new insights can be derived from them [81]. The
understanding of the genetic causes of male breast cancer is important because
it can drastically impact the medical management for patients and their rela-
tives.
As can be seen in Figure 4.16, the initial amount of DNA variants that can
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Figure 4.15: Quality assessment results for the Crohn case study.
be found in the genomic repositories is 117, with 1,266 articles associated and
21 genes under study. Nevertheless, only one population (European) has been
screened, in contrast with the other case studies, where the populations under
study were diverse.
Once the initial list of variants has been established, we performed the qual-
ity assessment to determine how many of them are relevant for genetic diagnosis.
Due to the number of men that suffer this cancer is low, none of the studies
associated to the variants pass the quality filters stablished in 700 cases and 700
controls. As a consequence none of the variants can be considered as relevant
according to our initial criteria.
After presenting the results to the stakeholders, they changed the quality
criteria to accept those studies performed over 500 individuals (cases and con-
trols). One of the strengths of the SILE method is its versatility, that allows





















Figure 4.16: Extraction and integration of the DNA variants associated with
male breast cancer.
the adjustment of the quality criteria depending on the context of the disease
under study without incrementing the cost of its performance. The results of
this new implementation are shown in Figure 4.17.
From the initial amount of 117 DNA variant, only 8 fulfill the new require-
ments. Most of the variants have been discarded due to the clinical significance
was not clear (likely benign, likely pathogenic or uncertain) or not relevant
enough.
From the variants selected as relevant, 6 of them have a moderate level of
evidence because there are two studies performed less than 3 years ago (2016
and 2017). The other variants have a limited level of evidence. A summary of
the information associated to the variants can be seen in Table 4.8.
The results from both complementary case studies were satisfactorily vali-
dated by the stakeholders, what corroborates the usefulness of the method in
different scenarios.
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Figure 4.17: Quality assessment results for the male breast cancer case study.
4.5 Conclusions
Throughout this chapter, we have validated the solution proposed in terms of
the adequacy of the contribution to fulfill the stakeholders goals. In order to
validate the accuracy of the method and its usefulness, we proposed two case
studies and developed the GeIS that supports the different stages of the process:
from the selection of the adequate data sources to the final exploitation of the
information.
As can be seen in both case studies, the management of genomic information
is a complex and time consuming task that requires a great effort from the
researchers if they do not have the support of a systematic process and a proper
information system support. The SILE method has been considered accurate
and useful for the stakeholders, as much from the precision of the results as
from the support to the management of the information to achieve new research
66 CHAPTER 4. TREATMENT VALIDATION
Table 4.8: Variants associated with the risk of suffering male breast cancer.
ID Gene Chromosome Clinical Significance Bib. ID/Year
rs1314913 RAD51B 14 Increased Risk
26248686 (2015)
23001122 (2012)
rs3803662 TOX3 16 Increased Risk
21949660 (2011)
23001122 (2012)
rs397507751 BRCA2 13 Pathogenic 28008555 (2017)
rs80359276 BRCA2 13 Pathogenic 28008555 (2017)
rs80359492 BRCA2 13 Pathogenic 28008555 (2017)
rs80359598 BRCA2 13 Pathogenic 26360800 (2016)
rs80359677 BRCA2 13 Pathogenic 28008555 (2017)
rs80359763 BRCA2 13 Pathogenic 28008555 (2017)
goals. As a result, two new implementations of the method were performed
at the request of the stakeholders: one for the study of the genetic causes of
Crohn disease and another one for male breast cancer. The results of these
implementations confirmed the usefulness of the SILE method, and open the
opportunity to propose SILE as a fundamental method to provide valuable
contents for those GeIS that are intended to become the cornerstone of the
modern Medicine of Precision.
Figure 4.18: Available phenotypes through the GenesLove.Me platform.
After the validation process, a fruitful communication path has been es-
tablished and new opportunities to check the validity of the method in other
projects have arisen. One of the projects is a collaboration with the child oncol-
ogy group of the Hospital La Fe (Valencia), focused on adding the genetic risk
of Neuroblastoma, a type of childhood cancer, to the clinical trials performed
in the patients in order to determine the effectiveness of the treatments.
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A second project derived from the results obtained in this thesis is the devel-
opment of an online platform that serves as basis for the genetic testing of the
studied phenotypes. The platform is called GenesLove.Me 12 and the users can
access the information about the DNA variants as well as the quality criteria
used to determine their relevance. Figure 4.18 shows the prototype interface
where the user can access the available phenotypes.
This prototype serves as basis for a bigger goal of the research center, the
development of an industrial platform for the management of genomic data that






We started this thesis by formulating the research questions associated to four
main goals: determine the problems that hinder the management of genomic
information, provide a method for the efficient management of genomic informa-
tion, provide a set of quality criteria to ensure that data are reliable a correct,
and validate the contribution of this research work.
After introducing the characteristics of genomic data sources and the pro-
blems to face when trying to connect and integrate the knowledge they collect,
we proposed a method (SILE) to manage the genomic information in an efficient
way. The method is supported by a conceptual model (the CSHG) that provides
the solid conceptual structure required to connect the genomic information. In
addition, the SILE method is also supported by a data quality methodology that
guarantees that the information managed is of enough quality. This ensures that
the conclusions derived from its analysis are reliable and accurate.
Finally, we tested the validity of the method by building a Genomic Infor-
mation System (GeIS) that supports its application in four case studies, and
verified the results with the stakeholders.
In this last chapter of the thesis, we use the results of this work to answer the
research questions we formulated in the first chapter (section 5.1), present its
impact in terms of publications, academic works and academic projects (section
5.2), and suggest directions for future work (section 5.3).
5.1 Answers to Research Questions
Throughout this research work, we have been working toward answers for the
research questions associated to the goals defined in the first chapter.
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5.1.1 Results of Objective 1
Along chapter 2, we answer the set of knowledge questions associated to the first
objective of this thesis: determine the problems that hinder the management of
genomic information.
RQ1. Where can the genomic information be found?
The advances in sequencing technologies, such as Next Generation Sequen-
cing (NGS) have allowed the development of multitude of research projects
around the world. Most of the knowledge generated by these projects are pu-
blicly available for the scientific community in over thousand online genomic
repositories. These resources are specialized databases that provide not only
information about DNA sequences, but also data on gene expression, macro-
molecular structures, gene-disease associations and genotype frequencies in di-
verse populations. Nowadays, there is no way of knowing with certainty the
number of active genomic data sources due to the information about them is
scattered in various life science journals and around the Web. Furthermore, a
significant number of them become obsolete quickly due to the loss of technolo-
gical maintenance or the lack of updates. We answered this question in section
2.1.
RQ2. Which problems arise when managing genomic information?
In order to understand complex biological systems and validate their experi-
ments, geneticists and researchers are forced to delve into a lake of information
as well as connect as much databases as possible. However, the genomic infor-
mation differs not only in its scope but also in the way the same concepts are
modeled. Along section 2.2, we describe the current efforts of the community
to provide ontologies and conceptual models to represent the key concepts of
the domain. In addition, due to the complexity of the biological processes, the
experimental nature of the research and the different techniques and protocols
used by the laboratories, there is a high variability in the quality of the results,
increasing the noise and the effort required to extract meaningful conclusions.
Following this premise, we performed a study of the most common errors present
in the genomic data sources (section 2.3), which helped us to define the prob-
lems that researchers must face when managing genomic information. These
problems can be summarized as: the selection of the adequate data sources, the
identification of high-quality data, and the storage and analysis of the informa-
tion with the aim of achieving competitive advantage.
5.1.2 Results of Objective 2
Along the first part of chapter 3 (section 3.1), we answered the set of re-
search questions associated with the second objective of this thesis: to provide
a method for the efficient management of genomic information.
The SILE method comprises 4 systematic stages (Search, Identification,
Load and Exploitation) and uses the Conceptual Schema of the Human Genome
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(CSHG) as the conceptual structure required to harmonize the information un-
der a holistic perspective.
RQ3. How can the most suitable genomic data sources be found?
The aim of the first stage of the method is to identify the genetic repositories
that store the information required to succeed in fulfilling the goals of a defined
task. By using a graphical interface developed for this purpose and the CSHG,
the researcher can explore new data sources, identify which ones are the most
adequate to extract information from, and ensure that not relevant repositories
have been left aside. This question has been answered in section 3.1.1.
RQ4. How can the relevant information be identified?
The aim of the second stage of the SILE method is to identify the required
information from each repository and harmonize it into a common data model
so it could be loaded into a database for its further exploitation. This requires
to have a deep knowledge of the underlying structure of each repository as well
as to define a set of extraction and transformation rules that are fully described
in section 3.1.2.
RQ5. How can the information be structured and stored for its further
exploitation?
The data coming from the genomic repositories must be transformed into a
queryable format to ensure its persistency and allow the extraction of knowledge.
Both tasks are performed in the third and fourth stages of the SILE method.
Along sections 3.1.3 and 3.1.4, we answer this research question and present a
tool called VarSearch that has been developed to this aim.
5.1.3 Results of Objective 3
The last part of chapter 3 (section 3.2) is dedicated to answer the set of research
questions associated to the third objective of this thesis: to provide a set of
quality criteria to ensure that data are reliable and correct.
RQ6. Which are the criteria that genomic information must fulfill to ensure
its quality?
Using the results of the study described in section 2.3, we determined a set
of quality dimensions and quality metrics that genomic information must fulfill
to ensure that the information managed is reliable and valuable.
RQ7. How can the quality of genomic information be measured?
In order to sistematically apply the dimensions and metrics, we defined a
Data Quality Methodology specially designed for genomic information. The
methodology has been applied in the Search and Identification stages of the
SILE method as explained in sections 3.2.2 and 3.2.3.
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Once the method and the quality criteria have been established, we per-
formed the validation by answering a new set of research questions.
RQ8. To which extent are the results of our method accurate and valid?
The accuracy of the SILE method was measured by determining the presence
of false positives and false negatives in the results obtained after its application
in a case study: the identification of the DNA variants associated to the risk of
suffering migraine, in order to perform a genetic diagnosis from a patient sample.
After the analysis of the results and the comparison with those obtained by the
stakeholders, we concluded that the results of the method are accurate for the
task at hand. The answer to this research question is explained in section
4.2.
RQ9. Do domain experts think that our method is useful to manage genomic
information?
To answer this research question we performed a second case study which
aim is the identification of potentially relevant biomarkers for the diagnosis of
a complex disease: epilepsy. After the analysis of the results, the stakeholders
have considered the method as useful so it was applied to two additional case
studies to complement their work: Crohn disease and male breast cancer. The
application of these case studies is detailed in sections 4.3 and 4.4.
5.2 Thesis Impact
This research work has been validated through the publication of the results in
different international forums. In addition, some academic works have been de-
veloped as complementary work as well as the participation in research projects.
In this section the mentioned contributions are summarized.
5.2.1 Publications
The results that have been obtained during the development of this research
have been published and presented in forums of high impact in the field of
Conceptual Modeling and Information Systems; all of them with international
projection:
A. León, O. Pastor, Infoxication in the Genomic Data Era and Implications
in the Development of Information Systems, Accepted in the IEEE Thirteen
International Conference on Research Challenges in Information Science (RCIS),
2019.
A. León, O. Pastor, Smart Data for Genomic Information Systems: the
SILE Method, in: Complex Systems Informatics and Modeling Quarterly Jour-
nal (CSIMQ), Article 97, Issue 17, pp. 1-–23, 2018.
A. León, A. Garćıa, J.C. Casamayor, J. Reyes, Genomic Data Management
in Big Data Environments: The Colorectal Cancer Case, in: Advances in Con-
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ceptual Modeling. ER 2018. Lecture Notes in Computer Science, vol 11158, pp.
319–329, 2018.
A. León, I. Pascual, O. Pastor, Genomic Information Systems applied to
Precision Medicine: Genomic Data Management for Alzheimer’s Disease Treat-
ment, in: Designing Digitalization (ISD2018 Proceedings), 2018.
A. León, O. Pastor, J.C. Casamayor, A Method to Identify Relevant Genome
Data: Conceptual Modeling for the Medicine of Precision, in: Proceedings ER,
pp. 597-–609, 2018.
A. León, O. Pastor, From Big Data to Smart Data: A Genomic Systems
Perspective, in: Proceedings RCIS, pp. 1-–11, 2018.
A. León, O. Pastor, Towards an Effective Medicine of Precision by using
Conceptual Modelling of the Genome, in Proceedings ICSE-SEHS, pp. 14-17,
2018.
A. León, J. Reyes, V. Burriel, F. Valverde, Data Quality Problems When
Integrating Genomic Information, in: ER 2016 Workshops. LNCS, Springer
International Publishing, pp. 173-–182, 2016.
Additional contributions:
In addition to the main publications, this research served as contribution for
different works that have been developed in parallel such as:
A. Escalera, A. León, O. Pastor, Sistemas de Información para una Medicina
de Precisión: Identificación de Variaciones Genómicas para el Diagnóstico del
Cáncer de Mama, Accepted in the XXII Ibero-American Conference on Software
Engineering (CibSE), 2019.
J.F. Reyes Román, A. León Palacio, O. Pastor López, Software Engineering
and Genomics: The Two Sides of the Same Coin?, in: Proceedings of the
12th International Conference on Evaluation of Novel Approaches to Software
Engineering, SCITEPRESS - Science and Technology Publications, pp. 301—
307, 2017.
V. Burriel, J.F. Reyes Román, A. Heredia Casanoves, C.E. Iñiguez-Jarŕın,
A. León Palacio, GeIS based on Conceptual Models for the Risk Assessment of
Neuroblastoma, in: 2017 11th International Conference on Research Challenges
in Information Science (RCIS), IEEE, pp. 451—452, 2017.
O.P. López, A.L. Palacio, J.F.R. Román, J.C. Casamayor, Modeling Life:
A Conceptual Schema-centric Approach to Understand the Genome, Concep-
tual Modeling Perspectives, Springer International Publishing, pp. 25—40,
2017.
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5.2.2 Academic Works
The research performed throughout this thesis work has allowed the lead and
development of several academic works that have contributed to the achievement
of the objectives, as well as the obtaining of the corresponding bachelor ’s and
master’s degrees by the students involved in them:
• Biotecnoloǵıa para la medicina de precisión: Identificación de
variaciones genómicas para el diagnóstico de cáncer de mama.
Final Degree Project in Biomedical Engineering (2018). Alba Escalera
Balsera. Advisor: Óscar Pastor López. Co-advisor: Ana León Palacio.
• Un proceso para la identificación sistemática de variaciones genó-
micas: Aplicaciones a la medicina de precisión. Master’s Thesis in
Software Engineering, Formal Methods and Information Systems (2018).
Simranpreet Kahur. Advisor: Óscar Pastor López. Co-advisor: Ana León
Palacio.
• Exploración de bases de datos genómicas dirigida por modelos
conceptuales. Master’s Thesis in Software Engineering, Formal Methods
and Information Systems (2018). Vanessa Soĺıs Cabrera. Advisor: Óscar
Pastor López. Co-advisor: Ana León Palacio.
In addition to the above mentioned works, three more master’s theses are
under development, two in the field of Biomedichal Engineering and one in the
field of Software Engineering.
5.2.3 Teaching Experience
It is also worth mentioning that another important result of this thesis has
been the generation of material that has been used for the development of the
teaching content of the following subjects:
• Contribution of the Biomedical Engineer: Bachelor’s Degree in
Biomedichal Engineering.
• Design and Management of Genomic Information Systems: Bache-
lor’s Degree in Computer Science Engineering.
• Bioinformatics: Bachelor’s Degree in Biomedichal Engineering.
• Information Systems Applied to Bioinformatics: Management
of Genomics Data: Master’s Degree in Software Engineering, Formal
Methods and Information Systems.
5.2.4 Research Projects
In addition to the above mentioned contributions, I have collaborated in the
following research projects:
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• Un Método de producción de software dirigido por modelos para
el desarrollo de aplicaciones Big Data (DataME). Spanish Ministry
of Science and Innovation. From December 2016 to December 2020. Ref.
TIN2016-80811-P.
• Innovative services for Digital Enterprises with ORCA (IDEO).
Generalitat Valenciana. From January 2014 to December 2017. Ref.
PROMETEO/2014/039.
5.3 Future Work
Based on the work proposed and the validation performed, in this section we
formulate directions for future work.
Along this research work, we applied the SILE method in a group of case
studies where its reliability and usefulness have been proved. However, the
complexity of the genetic causes of the diseases requires its application in as
many cases as possible to identify those situations where the method could be
improved to make it more useful. For instance, some diseases are caused by the
combination of DNA variants in more than one gene so it is required the study
of what is called haplotypes: a group of alleles in an organism that are inherited
together from a single parent. These alleles by itself are not relevant to develop
the disease, but when a combination of them are present the probabilities are
substantially increased which could affect the identification process and the
established quality criteria.
The SILE method has been validated by applying it to answer a specific
research question of interest for the stakeholders: the identification of DNA
variants associated to the risk of suffering a disease. Nevertheless, the method
can be applied to answer other research questions to cover different parts of
the biological domain such as proteomics and pharmacogenomics. To this end,
we must review the underlying conceptual schema to ensure that the required
elements are correctly defined and to formulate new case studies to validate its
reliability and usefulness.
Another important aspect of the proposed solution is to prove its validity to
update the information identified in a first application of the method. As has
been mentioned in the introduction, this domain is evolving at a fast pace and it
is very common that in a short period of time new findings that contradict the
current knowledge appear. Thus, it is important to verify that the information
remains valid. To this aim, it is required to determine the issues that could arise
during the update process and how the different stages of the method must be
applied.
The tools developed for the search of genomic databases and the information
system that assists the SILE method must be improved to enhance the user
experience. For example, due to the limitations of the metadata provided by the
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genomic repositories, part of the results provided by the GeIS must be manually
verified in order to assure its validity. The automation of this process, using text
mining to extract the required information from the literature, would improve
its efficiency and would bring significant time savings for researchers.
The technology used to store the information is a relational database, ne-
vertheless it would be interesting the study of the different database technologies
and their performance according to the task to achieve.
As a final conclusion, we found that the proposed method are a step in
the right direction, but we are aware that more research must be done and
more cases should be analyzed to verify the working of the method in a greater
number of situations. We continue in this line of work with the development
of new research projects and academic works, hoping to continue to show the
positive results we are achieving so far.
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ing interaction design patterns to extract knowledge from big data. In
Lecture Notes in Computer Science (including subseries Lecture Notes in
Artificial Intelligence and Lecture Notes in Bioinformatics), 2018.
[51] Carlo Batini, Cinzia Cappiello, Chiara Francalanci, and Andrea Maurino.
Methodologies for data quality assessment and improvement. ACM Com-
puting Surveys, 2009.
[52] Ana Leon Palacio and Oscar Pastor Lopez. From Big Data to Smart Data:
A Genomic Information Systems Perspective. In 2018 12th International
Conference on Research Challenges in Information Science (RCIS), pages
1–11. IEEE, 2018.
[53] M. Dawn Teare and Jennifer H. Barrett. Genetic linkage studies. In An
introduction to genetic epidemiology, pages 39–60. Bristol University Press,
2017.
[54] Cathryn M. Lewis and Jo Knight. Introduction to Genetic Association
Studies. Cold Spring Harbor Protocols, 2012(3), mar 2012.
[55] William S. Bush and Jason H. Moore. Chapter 11: Genome-Wide Associ-
ation Studies. PLoS Computational Biology, 8(12), dec 2012.
[56] Adnan Custovic and Angela Simpson. What are we learning from genetic
cohort studies? Paediatric Respiratory Reviews, 7:S90–S92, jan 2006.
[57] Eun Pyo Hong and Ji Wan Park. Sample Size and Statistical Power Cal-
culation in Genetic Association Studies. Genomics & Informatics, 2012.
[58] Magdalena Szumilas. Explaining odds ratios. Journal of the Canadian
Academy of Child and Adolescent Psychiatry, 2010.
[59] Itsik Pe’er, Roman Yelensky, David Altshuler, and Mark J. Daly. Estima-
tion of the multiple testing burden for genomewide association studies of
nearly all common variants. Genetic Epidemiology, 2008.
[60] Steven A McCarroll and David M Altshuler. Copy-number variation and
association studies of human disease. Nature Genetics, 39:S37, jun 2007.
[61] Bethesda (MD): National Center for Biotechnology Informa-
tion (US). PubMed Help, Accessed January 2019. Available from:
www.ncbi.nlm.nih.gov/books/NBK3827/.
82 BIBLIOGRAPHY
[62] P.A. Kitts, Deanna M. Church, F. Thibaud-Nissen, J. Choi, V. Hem,
V. Sapojnikov, R.G. Smith, T. Tatusova, C. Xiang, A. Zherikov, M. DiCuc-
cio, T.D. Murphy, K.D. Pruitt, and A. Kimchi. Assembly: a resource
for assembled genomes at ncbi. Nucleic Acids Research, 44(D1):D73–D80,
2016.
[63] Landrum et al. Clinvar: improving access to variant interpretations and
supporting evidence. Nucleic Acids Research, 46(D1):D1062–D1067, 2018.
[64] Zerbino et al. Ensembl 2018. Nucleic Acids Research, 46(D1):D754–D761,
2018.
[65] Kitts et al. The Database of Short Genetic Varia-
tion (dbSNP), Accessed January 2019. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK174586/.
[66] Murphy et al. Gene Help: Integrated Access to Genes of Genomes in the
Reference Sequence Collection, Accessed January 2019. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK3841/.
[67] Ewan Birney and Nicole Soranzo. The end of the start for population
sequencing. Nature, 526:52, sep 2015.
[68] National Center for Biotechnology Information. Entrez Pro-
gramming Utilities Help [Internet], Accessed April 2019.
https://www.ncbi.nlm.nih.gov/books/NBK25497/.
[69] Kinsella Rhoda et al. Ensembl BioMarts: A hub for data retrieval across
taxonomic space. Database, 2011.
[70] HUGO Gene Nomenclature Committee. REST web-service help, Accessed
April 2019. https://www.genenames.org/help/rest/.
[71] U.S. National Library of Medicine. Medical Subject Head-
ings - Preface, Accessed March 2019. Available from:
www.nlm.nih.gov/mesh/intro preface.html#pref rem.
[72] Richards et al. Standards and guidelines for the interpretation of sequence
variants: a joint consensus recommendation of the American College of
Medical Genetics and Genomics and the Association for Molecular Pathol-
ogy. Genetics in Medicine, 17(5):405–423, may 2015.
[73] Padhraig Gormley, Bendik S. Winsvold, Dale R. Nyholt, Mikko Kallela,
Daniel I. Chasman, and Aarno Palotie. Migraine genetics: from genome-
wide association studies to translational insights. Genome Medicine, 2016.
[74] Arn MJM van den Maagdenberg. Migraine genetics: New opportunities,
new challenges. Cephalalgia, 36(7):601–603, 2016.
[75] Candace T. Myers and Heather C. Mefford. Advancing epilepsy genetics
in the genomic era, 2015.
[76] Ingrid E. Scheffer. Epilepsy genetics revolutionizes clinical practice, 2014.
BIBLIOGRAPHY 83
[77] Celia Sintas, Oriel Carreno, Jessica Fernandez-Morales, Pilar Cacheiro,
Maria-Jesus Sobrido, Bernat Narberhaus, Patricia Pozo-Rosich, Alfons
Macaya, and Bru Cormand. A replication study of a GWAS finding in
migraine does not identify association in a Spanish case-control sample.
Cephalalgia : an international journal of headache, 32(14):1076–1080, oct
2012.
[78] Anttila Verneri et al. Genome-wide association study of migraine implicates
a common susceptibility variant on 8q22.1. Nature genetics, 42(10):869–
873, oct 2010.
[79] National Cancer Institute. Crohn disease, Accessed March 2019.
https://ghr.nlm.nih.gov/condition/crohn-disease.
[80] Jimmy Z. Liu and Carl A. Anderson. Genetic studies of Crohn’s disease:
Past, present and future. Best Practice & Research Clinical Gastroenterol-
ogy, 28(3):373–386, jun 2014.
[81] Breastcancer.org. Male Breast Cancer, Accessed March 2019.
https://www.breastcancer.org/symptoms/types/male bc.

A. CONCEPTUAL SCHEMA DESCRIPTION 85
A Conceptual Schema Description
Table A1: Conceptual Schema Description
Class Attribute Description
Assembly
assembly Name of the reference sequence
date assembly Date of the reference sequence
gh identifier Identifier provided by the UCSC Genomic Institute
Bibliography DB
url URL of the bibliography data source
name Name of the bibliography data source
Bibliography Reference
id Identifier of the publication
title Title of the publication
publication Formatted citation
authors List of authors
date Publication date
Chromosome
nc identifier Identifier of the chromosomic sequence of reference
name Name of the chromosome
CNV repetitions Number of times a sequence of nucleotides has been repeated
Databank
name Name of the data source
url URL of the data source
Databank Version
release Identifier of the release
date Release date
Deletion ref Sequence of nucleotides that has been deleted
Gene
ng identifier Identifier of the genomic sequence of reference
start Start of the gene in the DNA sequence
end End of the gene in the DNA sequence
symbol Symbol of the gene
official name Official name of the gene
description Description of the gene
synonyms Any other names used to represent the gene
Imprecise description Description of the variation
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Table A2: Conceptual Schema Description (Cont.)
Class Attribute Description
Indel
ref Sequence of nucleotides that has been deleted
alt Sequence of nucleotides that has been inserted
Insertion alt Sequence of nucleotides that has been inserted
Inversion alt Sequence of nucleotides that has been inverted
Phenotype
phenotype id Identifier of the phenotype
name Name of the phenotype
Population
id Identifier of the population
name Name of the population
size How many people conforms the studied population
Population DB
name Name of the database
description Description of the database
url URL of the database
Precise
start Start of the variation in the DNA sequence
end End of the variation in the DNA sequence
SNP Allele allele Sequence of nucleotides that conforms the allele
SNP Allele Population frequency Appearance frequency of the allele in the population
SNP Genotype
allele1 Sequence of nucleotides in one strand of the chromosome
allele2 Sequence of nucleotides in the other strand of the chromosome
SNP Genotype Population frequency Frequency of the genotype in the studied population
Statistical Evidence
replicated Wheter the study has been replicated
sample How many people participates in the study
OR Odds Ratio
IC Interval of Confidence
p value p-value
Variation
db variation id Identifier of the variation provided by the data source
clinically importance Effect of the variation
other identifiers HGVS expressions associated to the variation
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B Mapping Rules
Table B1: Mapping Rules
Assembly(assembly,-,-) ⊇ ClinVar.assembly set(assembly name,-,-)
Assembly(assembly, date assembly, hg identifier) ⊇ Assembly(assemblyname, seqreleasedate, ucscname)
Bibliography DB(ulr, name) ⊇ PubMed(“https://www.ncbi.nlm.nih.gov/pubmed/”,
“PubMed”)
Bibliography Reference (id, title, publication, au-
thors, date)
⊇ PubMed.DocSum(Id, Title, comb(Title, AuthorList,
tr(PubDate), Volume, Issue, Pages, FullJournalName),
comb(AuthorList), tr(DatePub))
Bibliography Reference (id,-,-,-,-) ⊇ GWAS(PUBMEDID,-,-,-,-)
Bibliography Reference(id,-,-,-,-) ⊇ ClinVar.IdList(Id,-,-,-,-)
Bibliography Reference(id,-,-,-,-) ⊇ Ensembl(pmid,-,-,-,-)
Chromosome(-, name) ⊇ GWAS(-, CHR ID)
Chromosome(-, name) ⊇ ClinVar.assembly set(-, chr)
Chromosome(-, name) ⊇ Ensembl(-, chr name)
Chromosome(nc identifier, name) ⊇ dbSNP.DocSum(tr(DOCSUM), CHR)
Chromosome(nc identifier, name) ⊇ EG.GenomicInfoType(ChrAccVer, ChrLoc)
Databank(name, url) ⊇ GWAS(“GWAS Catalog”,
“https://www.ebi.ac.uk/gwas/home”)
Databank(name, url) ⊇ ClinVar(“ClinVar”,
“https://www.ncbi.nlm.nih.gov/clinvar/”)
Databank(name, url) ⊇ Ensembl(“Ensembl”,
“https://www.ensembl.org/index.html”)
Databank(name, url) ⊇ dbSNP(“dbSNP”,
“https://www.ncbi.nlm.nih.gov/projects/SNP/”)
Databank(name, url) ⊇ HGNC(“HGNC”, “https://www.genenames.org/”)
Databank(name, url) ⊇ Gene(“Entrez Gene”,
“https://www.ncbi.nlm.nih.gov/gene/”)
Databank(name, url) ⊇ Assembly(“NCBI Assembly”,
“https://www.ncbi.nlm.nih.gov/assembly/”)
Databank Version(release, date) ⊇ GWAS(“v1.0.2”, “2018-10-29”)
Databank Version(release, date) ⊇ ClinVar(DbBuild, LastUpdate)
Databank Version(release, date) ⊇ Ensembl(“94”, “October 2018”)
Databank Version(-, date) ⊇ LF(-, “March 13, 2018”)
Databank Version(release, date) ⊇ dbSNP(DbBuild, LastUpdate)
Databank Version(-, date) ⊇ HGNC(-, lastModified)
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Table B2: Mapping Rules (Cont. I)
Databank Version(release, date) ⊇ Gene(DbBuild, LastUpdate)
Databank Version(release, date) ⊇ Assembly(DbBuild, LastUpdate)
Deletion(ref) ⊇ ClinVar.assembly set(ref)
Gene(-,-,-, symbol,-,-,-) ⊇ GWAS(-,-,-, MAPPED GENE,-,-,-)
Gene(-,-,-, symbol,-,-,-) ⊇ ClinVar.gene(-,-,-, symbol,-,-,-)
Gene(-,-,-, symbol,-,-,-) ⊇ Ensembl(-,-,-, associated gene,-,-,-)
Gene(ng identifier,-,-, symbol,-,-,-) ⊇ dbSNP.DocSum(tr(DOCSUM),-,-, GENE,-,-,-)
Gene(-,-,-, symbol, official name,-, synonyms) ⊇ HGNC.doc(-,-,-, symbol, name,-, com(alias symbol))
Gene(-,-,-, symbol, official name, description, synonyms) ⊇ EG.DocumentSummary(-,-,-,NomenclatureSymbol,
NomenclatureName, Summary, OtherAliases)
Gene(-, start, end,-,-,-,-) ⊇ EG.GenomicInfoType(-, ChrStart, ChrStop,-,-,-,-)
Indel(alt) ⊇ GWAS(tr(STRONGEST SNP-RISK ALLELE))
Indel(ref, alt) ⊇ ClinVar.assembly set(ref, alt)
Indel(-,alt) ⊇ Ensembl(-, associated variant risk allele)
Insertion(alt) ⊇ GWAS(tr(STRONGEST SNP-RISK ALLELE))
Insertion(alt) ⊇ ClinVar.assembly set(alt)
Insertion(alt) ⊇ Ensembl(associated variant risk allele)
Inversion(alt) ⊇ GWAS(tr(STRONGEST SNP-RISK ALLELE))
Inversion(alt) ⊇ ClinVar.assembly set(alt)
Inversion(alt) ⊇ Ensembl(associated variant risk allele)
Phenotype(-, name) ⊇ ClinVar.trait(-, trait name)
Phenotype(-, name) ⊇ GWAS(-, MAPPED TRAIT)
Phenotype(-, name) ⊇ Ensembl(-, phenotype description)
Population(id, name, size) ⊇ 1G.populations(tr(population))
Population(-, name, size) ⊇ dbSNP.DocSum(-, GLOBAL POPULATION,
GLOBAL SAMPLESIZE)
Population DB(name,-, url) ⊇ 1000Genomes(“1000 Genomes”,-,
“https://www.ensembl.org/index.html”)
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Table B3: Mapping Rules (Cont. II)
Precise(-, start,-) ⊇ GWAS(-, CHR POS, -)
Precise(start, end) ⊇ ClinVar.assembly set(start, stop)
Precise(specialization type,-,-) ⊇ ClinVar.variation(tr(variant type,-,-))
Precise(-, start, end) ⊇ Ensembl(-, chrom start, chrom end)
Precise(specialization type, start,-) ⊇ dbSNP.DocSum(SNP CLASS, tr(CHRPOS),-)
SNP Allele(allele) ⊇ Ensembl(minor allele)
SNP Allele(allele) ⊇ 1G.populations(allele)
SNP Allele Population(frequency) ⊇ Ensembl(minor allele frequency)
SNP Allele Population(frequency) ⊇ 1G.populations(frequency)
SNP Allele Population(frequency) ⊇ dbSNP.DocSum(GLOBAL MAF)
SNP Genotype(allele1, allele2) ⊇ 1G.population genotypes(genotye)
SNP Genotype Population(frequency) ⊇ 1G.population genotypes(frequency)
Statistical Evidence(replicated, sample, OR, CI, p value) ⊇ GWAS(tr(REPLICATION SAMPLE SIZE), INI-
TIAL SAMPLE SIZE, OR or BETA, 95% CI, P-
VALUE)
Statistical Evidence(-,-,-,-, p value) ⊇ Ensembl(-,-,-,-, p value)
Variation(db variation id,-,-,-) ⊇ GWAS(comb(tr(SNP ID CURRENT), STUDY
ACCESSION,-,-)
Variation(db variation id,-,-) ⊇ ClinVar.variation(comb(measure id,tr(db id)),-,-)
Variation(-, clinically importance,-) ⊇ ClinVar.clinical significance(-, description,-)
Variation(db variation id, clinically importance,-) ⊇ Ensembl(refsnp id,clinical significance,-)





C Variant Type Mapping
Table C1: Variant Type Mapping
Source Databases Conceptual Schema
Alu Deletion Deletion
Alu Insertion Insertion
Complex Chromosomal Rearrangement Precise
Complex Substitution Substitution
Copy Number Gain CNV
Copy Number Loss Deletion














Mobile Element Deletion Deletion
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Table C2: Variant Type Mapping (Cont.)
Source Databases Conceptual Schema
Mobile Element Insertion Deletion
Monomeric Repeat CNV
Multiple Nucleotide Polymorphism SNP
Multiple Nucleotide Variation Indel
No Alteration Imprecise
Novel Sequence Insertion Insertion
Sequence Alteration Variation








D Variants associated with Epilepsy
Table D1: Variants associated with the risk of suffering Epilepsy.
ID Gene Chromosome Clinical Significance Bib. ID/Year
rs12744221 RNF115 1 Association 23962720 (2014)
rs72698613 4 Association 23962720 (2014)
rs61670327 5 Association 23962720 (2014)
rs492146 GSTA4 6 Association 23962720 (2014)
rs72700966 PTPRD 9 Association 23962720 (2014)
rs143536437 ARHGAP11B 15 Association 23962720 (2014)
rs11861787 16 Association 23962720 (2014)
rs771390 C1orf94 1 Association 22949513 (2012)
rs13026414 2 Association 22949513 (2012)
rs11890028 SCN1A 2 Association 22949513 (2012)
rs72823592 NFE2L1 17 Association 22949513 (2012)
rs12720541 PLA2G4A 1 Association 22949513 (2012)
rs2717068 2 Association 22949513 (2012)
rs10496964 ZEB2 2 Association 22949513 (2012)
rs10030601 4 Association 22949513 (2012)
rs12059546 CHRM3 1 Association 22949513 (2012)
rs39861 MAST4 5 Association 22949513 (2012)
rs6732655 SCN1A 2 Association 25087078 (2014)
rs28498976 PCDH7 4 Association 25087078 (2014)
rs111577701 GOLIM4 3 Association 25087078 (2014)
rs535066 GABRA2 4 Association 25087078 (2014)
rs12987787 SCN1A 2 Association 25087078 (2014)
rs2947349 VRK2, FANCL 2 Association 25087078 (2014)
rs1939012 MMP8 11 Association 25087078 (2014)
rs1044352 PCDH7 4 Association 25087078 (2014)
rs55670112 5 Association 25087078 (2014)
rs7587026 SCN1A 2 Association 25087078 (2014)
rs346291 6 Association 20522523 (2010)
rs2601828 ADCY9 16 Association 20522523 (2010)
rs1490157 ZNF385D 3 Association 20522523 (2010)
rs16944 IL1B 2 Association 22160471 (2012)
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E Variants associated with Crohn’s Disease
Table D2: Variants associated with the risk of suffering Crohn’s disease.
ID Gene Chromosome Clinical Significance Bib. ID/Year











rs10210302 ATG16L1 2 Association 17554300 (2007)
rs10889677 IL23R 1 Association
26678098 (2015)
17786191 (2007)





rs1128535 TRAIP 3 Association 18200509 (2008)
rs11805303 IL23R 1 Association 21253534 (2010)
rs12037606 Association 17554300 (2007)








rs17221417 NOD2 16 Association 17554300 (2007)
rs17234657 intergenic 5 Association 19174780 (2009)
rs1793004 NELL1 11 Association 17684544 (2007)
rs1800629 TNF 6 Drug Response 12190096 (2002)
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Table D3: Variants associated with the risk of suffering Crohn’s disease. (Cont.)
ID Gene Chromosome Clinical Significance Bibliography ID
rs1992660 PTGER4 5 Association 17684544 (2007)
rs1992662 PTGER4 5 Association 17684544 (2007)
rs2076756 NOD2 16 Association
21209938 (2010)
17684544 (2007)
rs2201841 IL23R 1 Association
20066736 (2010)
17068223 (2006)






















rs6596075 IBD5 5 Association 17554300 (2007)
rs6601764 10 Association 17554300 (2007)
rs6908425 CDKAL1 6 Association
17554300 (2007)
18587394 (2008)
rs7076156 ZNF365 10 Risk Factor 21257989 (2011)
rs7753394 6 Association 17554300 (2007)
rs7807268 7 Association 17554300 (2007)
rs8111071 19 Association 17554300 (2007)
rs9469220 6 Association 17554300 (2007)
rs10761659 IL23R 10 Association 17554300 (2007)
